A paradigm for macular pigment photostability

Abstract

Visible light absorbing compounds are described. The compounds have a visible light absorption maximum of 430 nm to 480 nm and a full width at half maximum (FWHM) at the visible light absorption maximum of at least 35 nm and at most 100 nm, and the compounds are photostable. The compounds substantially mimic the visible light absorption characteristics of macular pigment while maintaining photostability. The compounds may be used in a variety of articles, including ophthalmic devices.

Description

[Technical Field]

[0001] (CROSS-REFERENCE TO RELATED APPLICATIONS) This application claims priority to U.S. Patent Application No. 16 / 898,638 (filed June 11, 2020) and U.S. Provisional Patent Application No. 62 / 867,968 (filed June 28, 2019), both of which are incorporated herein by reference in their entireties.

[0002] FIELD OF THE INVENTION The present invention relates to visible light absorbers. More specifically, the present invention relates to compounds that substantially mimic the visible light absorption properties of macular pigment while maintaining photostability. The compounds may be used in a variety of articles, including ophthalmic devices. [Background technology]

[0003] Human ocular tissue contains the dietary carotenoids lutein (L) and zeaxanthin (Z), collectively known as macular pigments (MP). Several reports have documented the benefits of MP, for example, as a short-wavelength (blue light) filter and as a potent antioxidant. MP is also thought to play a protective role against age-related macular degeneration (AMD) (Bernstein, P.S., Li, B., Vachali, P.P., Gorusupudi, A., Shyam, R., Henriksen, B.S., Nolan, J. M. Prog. Retin. Eye Res. 2016, 50, 34-66; Beatty, S., Boulton, M., Koh, H.H., Murray, I., J. Br. J. Ophthalmol. 1999, 83, 867-877). Macular pigment has further been found to be significantly correlated with light stress recovery time, reduced visual acuity glare contrast threshold, and reduced visual discomfort (Stringham, JM, Garcia., PV, Smith, PA, McLin, L, N., Foutch, BKIOVS, 2011, 52(10)7406-7415).

[0004] The chemicals associated with macular pigments are carotenoid derivatives that have extensive unsaturation and are highly reactive to olefin isomerization and oxidation upon photoexcitation. The antioxidant protection mechanism offered by carotenoids is sacrificial in nature; excitation of the pi system leads to reaction of its excited state with triplet oxygen, thereby protecting / limiting the excitation and reaction of other photosensitive compounds in the ocular environment. See, for example, Ribeiro et al., Food and Chemical Toxicology, Vol. 120, pp. 681-699 (2018); Burton et al., Can. J. Chem., Vol. 92, pp. 305-316 (2014); Ty et al., Journal of Oil Palm Research Vol. II No. 1, pp. 62-78 (June 1999); Johnston et al., Plos One, Vol. 9(10), pp. 1-10 (2014); and Boon et al., Critical Reviews in Food Science and Nutrition, Vol. 50, pp. 515-532 (2010). Summary of the Invention [Problem to be solved by the invention]

[0005] While it is desirable to incorporate macular pigments into products to provide eye protection, the overall lack of stability (thermal, oxidative, and photochemical) of carotenoids poses a significant obstacle to the development of such products. Therefore, it would be a significant advance if new stable materials could be developed that mimic the light absorption properties of macular pigments. [Means for solving the problem]

[0006] The present invention relates to compounds that exhibit a visible light absorption spectrum between 400 nm and 500 nm, a wavelength range that substantially mimics the spectrum of macular pigment. Such compounds are also photostable, even when measured for change / loss of absorption properties when exposed to conditions similar to those described in ICH Q1B, for example. Furthermore, the compounds may exhibit high extinction coefficients at desired wavelengths between 400 nm and 500 nm and therefore may be used at low concentrations to provide their light absorption effect. The compounds described herein may be used, for example, in ophthalmic devices to, for example, supplement the wearer's macular pigment optical density (MPOD).

[0007] Thus, in one aspect, the present invention provides a compound having a visible light absorption maximum of 430 nm to 480 nm and a full width at half maximum (FWHM) at the visible light absorption maximum of at least 35 nm and at most 100 nm, wherein the compound is photostable.

[0008] In another aspect, the present invention provides compounds having a visible light absorption maximum of 430 nm to 480 nm and a full width at half maximum (FWHM) at the visible light absorption maximum of at least 35 nm and at most 100 nm, which compounds are more photostable than macular pigment.

[0009] In a further aspect, the present invention provides a compound comprising a chromophore, the chromophore having a substructure of formula I:

[0010] [ka] wherein EWG in each occurrence is independently an electron-withdrawing group.

[0011] In a still further aspect, the present invention provides an ophthalmic device comprising a compound described herein. [Brief explanation of the drawings]

[0012] [Figure 1] 1 shows the UV-VIS transmission spectrum of an exemplary compound A of the present invention in a 0.2 mM methanol solution. [Figure 2] 1 shows the UV-VIS absorbance spectrum of Compound A of the present invention in a 0.2 mM solution in methanol overlaid on a literature spectrum of macular pigment. [Figure 3] 1 shows the absorbance spectra of contact lenses prepared from Compound A after exposure to light for up to 40 hours. DETAILED DESCRIPTION OF THE INVENTION

[0013] It is to be understood that the invention is not limited to the details of construction or process steps set forth in the following description, as the invention is capable of other embodiments and of being practiced or carried out in various ways using the teachings set forth herein.

[0014] The following definitions are provided for terms used in this disclosure.

[0015] Unless otherwise specified, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. The definition of polymer is consistent with the definition disclosed in Compendium of Polymer Terminology and Nomenclature, IUPAC Recommendations 2008, edited by: Richard G. Jones, Jaroslav Kahovec, Robert Stepto, Edward S. Wilks, Michael Hess, Tatsuki Kitayama, and W. Val Metanomski. All publications, patent applications, patents, and other references mentioned herein are incorporated herein by reference.

[0016] As used herein, the term "(meth)" refers to any methyl substitution. Thus, a term such as "(meth)acrylate" refers to both methacrylate and acrylate.

[0017] Wherever a chemical structure is depicted, it should be understood that the disclosed options for substituents in the structure may be combined in any combination. * and R ** and each of these contains a list of three possible groups, then nine combinations are disclosed. The same is true for combinations of properties.

[0018] General formula [ *** ] n When a subscript, such as "n" in {overscore (R)} is used to denote the number of repeating units in a chemical formula of a polymer, the formula should be interpreted as representing the number average molecular weight of the polymer.

[0019] The term "individual" includes humans and vertebrates.

[0020] The term "biomedical device" refers to any article designed to be used in or on mammalian tissue or fluid, preferably human tissue or fluid. Examples of these devices include, but are not limited to, wound dressings, sealants, tissue prostheses, drug delivery systems, coatings, adhesion barriers, catheters, implants, stents, and ophthalmic devices such as intraocular lenses and contact lenses. The biomedical device may be an ophthalmic device, specifically a contact lens, most specifically a contact lens made from silicone hydrogel or conventional hydrogel.

[0021] The term "ocular surface" includes the surface and glandular epithelium of the cornea, conjunctiva, lacrimal gland, accessory lacrimal gland, nasolacrimal duct, and meibomian gland, as well as their apical and basal matrices, puncta, and adjacent or associated structures, including the eyelids, which are connected as a functional system by both epithelial continuity through innervation and by the endocrine and immune systems.

[0022] The term "ophthalmic device" refers to any optical device that resides in or on the eye or any portion of the eye (including the ocular surface). These devices can provide optical correction, appearance enhancement, vision enhancement, therapeutic effects (e.g., as a dressing), or delivery of active ingredients such as pharmaceutical and nutritional supplements, or any combination of the foregoing. Examples of ophthalmic devices include, but are not limited to, lenses, optical inserts, and ocular inserts (including, but not limited to, punctal plugs). "Lens" includes spectacle lenses, sunglass lenses, soft contact lenses, hard contact lenses, hybrid contact lenses, intraocular lenses, and overlay lenses. Ophthalmic devices may include contact lenses.

[0023] The term "contact lens" refers to an ophthalmic device that can be placed on the cornea of ​​an individual's eye. Contact lenses may provide corrective, cosmetic, or therapeutic benefits, including wound healing, delivery of medications or nutritional supplements, diagnostic evaluation or monitoring, ultraviolet absorption, visible light or glare reduction, or any combination thereof. Contact lenses may be of any suitable material known in the art and may be soft lenses, hard lenses, or hybrid lenses containing at least two distinct portions with different physical, mechanical, or optical properties, such as modulus of elasticity, water content, light transmission, or a combination thereof.

[0024] Spectacle lenses or sunglasses may be composed of mineral materials, for example, based on silicates, or may be made from organic materials such as polycarbonates, polyamides, polyimides, polysulfones, polyethylene terephthalate / polycarbonate copolymers, and various other materials well known in the art.

[0025] The biomedical devices, ophthalmic devices, and lenses of the present invention may be composed of silicone hydrogels or conventional hydrogels, which typically contain at least one hydrophilic monomer and at least one silicon-containing component covalently bonded to each other within the cured device.

[0026] By "target macromolecule" is meant a macromolecule that has been synthesized from a reactive monomer mixture, including monomers, macromers, prepolymers, crosslinkers, initiators, additives, diluents, and the like.

[0027] The term "polymerizable compound" means a compound containing one or more polymerizable groups. This term includes, for example, monomers, macromers, oligomers, prepolymers, crosslinkers, and the like.

[0028] A "polymerizable group" is a group capable of undergoing free radical and / or cationic polymerization, e.g., chain growth polymerization, such as a carbon-carbon double bond that can polymerize when exposed to radical polymerization initiating conditions. Non-limiting examples of free radical reactive groups include (meth)acrylate, styrene, vinyl ether, (meth)acrylamide, N-vinyl lactam, N-vinyl amide, O-vinyl carbamate, O-vinyl carbonate, and other vinyl groups. Preferably, the free radical polymerizable group comprises (meth)acrylate, (meth)acrylamide, N-vinyl lactam, N-vinyl amide, and styryl functional groups, as well as mixtures of any of the foregoing. More preferably, the free radical polymerizable group comprises (meth)acrylate, (meth)acrylamide, and mixtures thereof. The polymerizable group may be unsubstituted or substituted. For example, the nitrogen atom in (meth)acrylamide may be bonded to hydrogen, or the hydrogen may be substituted with alkyl or cycloalkyl (which may themselves be further substituted).

[0029] Any type of free radical polymerization can be used, including but not limited to bulk, solution, suspension, and emulsion, as well as any controlled radical polymerization method, such as stable free radical polymerization, nitroxide-mediated living polymerization, atom transfer radical polymerization, reversible addition-fragmentation chain transfer polymerization, organotellurium-mediated living radical polymerization, etc.

[0030] A "monomer" is a monofunctional molecule that can undergo chain growth polymerization, particularly free radical polymerization, thereby creating repeating units within the chemical structure of a target macromolecule. Some monomers have difunctional impurities that can act as crosslinkers. A "hydrophilic monomer" is also a monomer that, when mixed with deionized water at a concentration of 5% by weight at 25°C, gives a clear, single-phase solution. A "hydrophilic component" is a monomer, macromer, prepolymer, initiator, crosslinker, additive, or polymer that, when mixed with deionized water at a concentration of 5% by weight at 25°C, gives a clear, single-phase solution. A "hydrophobic component" is a monomer, macromer, prepolymer, initiator, crosslinker, additive, or polymer that is slightly soluble or insoluble in deionized water at 25°C.

[0031] A "macromolecule" is an organic compound having a number average molecular weight greater than 1500, and may be reactive or non-reactive.

[0032] A "macromonomer" or "macromer" is a macromolecule having one group capable of undergoing chain-growth polymerization, particularly free-radical polymerization, thereby creating repeating units within the chemical structure of a target macromolecule. Generally, the chemical structure of a macromer differs from the chemical structure of a target polymer; i.e., the repeating units of the pendant group of the macromer differ from the repeating units of the target polymer or its backbone. The only differences between a monomer and a macromer are the chemical structure of the pendant group, the molecular weight, and the molecular weight distribution. Consequently, and as used herein, patent literature sometimes defines a monomer as a polymerizable compound having a relatively low molecular weight of about 1,500 daltons or less, which essentially includes some macromers. Specifically, monomethacryloxypropyl-terminated, mono-n-butyl-terminated polydimethylsiloxane (molecular weight = 500-1500 g / mol) (mPDMS) and mono-(2-hydroxy-3-methacryloxypropyl)-propyl ether-terminated, mono-n-butyl-terminated polydimethylsiloxane (molecular weight = 500-1500 g / mol) (OH-mPDMS) are sometimes referred to as monomers or macromers. Furthermore, patent literature sometimes defines macromers as having one or more polymerizable groups, essentially expanding the general definition of macromer to include prepolymers. Consequently, and as used herein, difunctional and multifunctional macromers, prepolymers, and crosslinkers may be used interchangeably.

[0033] A "silicon-containing component" is a monomer, macromer, prepolymer, crosslinker, initiator, additive, or polymer in the reactive mixture that has at least one silicon-oxygen bond, usually in the form of a siloxy group, a siloxane group, a carbosiloxane group, and mixtures thereof.

[0034] Examples of silicon-containing components useful in the present invention are disclosed in U.S. Pat. Nos. 3,808,178, 4,120,570, 4,136,250, 4,153,641, 4,740,533, 5,034,461, 5,070,215, 5,244,981, 5,314,960, 5,331,067, 5,371,147, 5,760,100, 5,849,811, 5,96 No. 2,548, No. 5,965,631, No. 5,998,498, No. 6,367,929, No. 6,822,016, No. 6,943,203, No. 6,951,894, No. 7,052,131, No. No. 7,247,692, No. 7,396,890, No. 7,461,937, No. 7,468,398, No. 7,538,146, No. 7,553,880, No. 7,572,841, No. 7,666,921 No. 7,691,916, No. 7,786,185, No. 7,825,170, No. 7,915,323, No. 7,994,356, No. 8,022,158, No. 8,163,206, No. 8,273 ,802, No. 8,399,538, No. 8,415,404, No. 8,420,711, No. 8,450,387, No. 8,487,058, No. 8,568,626, No. 8,937,110, No. 8 Nos. 8,937,111, 8,940,812, 8,980,972, 9,056,878, 9,125,808, 9,140,825, 9,156,934, 9,170,349, 9,217,813, 9,244,196, 9,244,197, 9,260,544, 9,297,928, 9,297,929, and European Patent No. 080539, which are incorporated herein by reference in their entireties.

[0035] A "polymer" is a target macromolecule made up of repeating units of the monomers used during polymerization.

[0036] A "homopolymer" is a polymer made from one monomer, a "copolymer" is a polymer made from two or more monomers, and a "terpolymer" is a polymer made from three monomers. A "block copolymer" consists of compositionally distinct blocks or segments. A diblock copolymer has two blocks. A triblock copolymer has three blocks. A "comb or graft copolymer" is made from at least one macromer.

[0037] A "repeating unit" is the smallest group within a polymer that corresponds to the polymerization of a particular monomer or macromer.

[0038] An "initiator" is a molecule that can decompose into radicals that can subsequently react with monomers to initiate a free-radical polymerization reaction. Thermal initiators decompose at a specific rate depending on the temperature; typical examples are azo compounds such as 1,1'-azobisisobutyronitrile and 4,4'-azobis(4-cyanovaleric acid); peroxides such as benzoyl peroxide, tert-butyl peroxide, tert-butyl hydroperoxide, tert-butyl peroxybenzoate, dicumyl peroxide, and lauroyl peroxide; peracids such as peracetic acid and potassium persulfate; and various redox systems. Photoinitiators decompose by a photochemical process; typical examples are derivatives of benzil, benzoin, acetophenone, benzophenone, camphorquinone, and mixtures thereof, as well as various monoacyl and bisacylphosphine oxides and combinations thereof.

[0039] A "crosslinker" is a di- or polyfunctional monomer or macromer that can undergo free radical polymerization at two or more positions on the molecule, thereby creating branch points and a polymer network. Common examples are ethylene glycol dimethacrylate, tetraethylene glycol dimethacrylate, trimethylolpropane trimethacrylate, methylene bisacrylamide, triallyl cyanurate, etc.

[0040] A "prepolymer" is a reaction product of monomers that contain remaining polymerizable groups that can undergo further reaction to form a polymer.

[0041] A "polymer network" is a cross-linked macromolecule that can swell but cannot dissolve in a solvent. A "hydrogel" is a polymer network that swells in water or an aqueous solution, typically absorbing at least 10% water by weight. A "silicone hydrogel" is a hydrogel made from at least one silicon-containing component along with at least one hydrophilic component. The hydrophilic component may also include a non-reactive polymer.

[0042] "Conventional hydrogel" refers to a polymer network made from components that do not have any siloxy, siloxane, or carbosiloxane groups. Conventional hydrogels are prepared from reactive mixtures that include hydrophilic monomers. Examples include 2-hydroxyethyl methacrylate ("HEMA"), N-vinylpyrrolidone ("NVP"), N,N-dimethylacrylamide ("DMA"), or vinyl acetate. U.S. Patent Nos. 4,436,887, 4,495,313, 4,889,664, 5,006,622, 5,039459, 5,236,969, 5,270,418, 5,298,533, 5,824,719, 6,420,453, 6,423,761, 6,767,979, 7,934,830, 8,138,290, and 8,389,597 disclose the formation of conventional hydrogels. Commercially available conventional hydrogels include, but are not limited to, etafilcon, genfilcon, hilafilcon, lenefilcon, nesofilcon, omafilcon, polymacon, and vifilcon (including all variants thereof).

[0043] "Silicone hydrogel" means a polymer network made from at least one hydrophilic component and at least one silicon-containing component. Examples of silicone hydrogels include acquafilcon, asmofilcon, balafilcon, comfilcon, delefilcon, enfilcon, fanfilcon, formofilcon, galyfilcon, lotrafilcon, narafilcon, and the like. In addition to rafilcon, riofilcon, samfilcon, senofilcon, somofilcon, and stenfilcon (including all of their variants), U.S. Patent Nos. 4,659,782, 4,659,783, 5,244,981, 5,314,960, 5,331,067, 5,371,147, 5,998,498, 6,087,499, and 6,107,499 are also disclosed. No. 15, No. 5,760,100, No. 5,776,999, No. 5,789,461, No. 5,849,811, No. No. 5,965,631, No. 6,367,929, No. 6,822,016, No. 6,867,245, No. 6,943, No. 203, No. 7,247,692, No. 7,249,848, No. 7,553,880, No. 7,666,921, No. No. 7,786,185, No. 7,956,131, No. 8,022,158, No. 8,273,802, No. 8,399, 538, 8,470,906, 8,450,387, 8,487,058, 8,507,577, No. 8,637,621, No. 8,703,891, No. 8,937,110, No. 8,937,111, No. 8,940 , No. 812, No. 9,056,878, No. 9,057,821, No. 9,125,808, No. 9,140,825, No. 9156,934, No. 9,170,349, No. 9,244,196, No. 9,244,197, No. 9,260,544, 9,297,928, 9,297,929, and silicone hydrogels such as those prepared in WO 03 / 22321, WO 2008 / 061992, and U.S. Patent Application Publication No. 2010 / 0048847, all of which are incorporated herein by reference in their entireties.

[0044] An "interpenetrating polymer network" comprises two or more networks that are at least partially entangled on a molecular scale, but that are not covalently bonded to each other and cannot be separated without interlocking chemical bonds. A "semi-interpenetrating polymer network" comprises one or more networks and one or more polymers characterized by some intermixing at the molecular level between at least one network and at least one polymer. A mixture of different polymers is a "polymer blend." Although a semi-interpenetrating polymer network is technically a polymer blend, in some cases the polymers are entangled so that they cannot be easily removed.

[0045] "Reactive components" are polymerizable compounds (such as monomers, macromers, oligomers, prepolymers, and crosslinkers) in the reactive mixture (defined below), as well as any other components in the reactive mixture that are intended to substantially remain in the resulting polymer network after polymerization and after all workup (extraction) and packing steps are complete. Reactive components may be retained within the polymer network by covalent bonds, hydrogen bonds, electrostatic interactions, the formation of an interpenetrating polymer network, or any other means. Components that are intended to be released from the polymer network during use are still considered "reactive components." For example, medicinal or nutritional ingredients in contact lenses that are intended to be released during wear are considered "reactive components." Components that are intended to be removed from the polymer network during the manufacturing process (e.g., by extraction), such as diluents, are not "reactive components."

[0046] The terms "reactive mixture" and "reactive monomer mixture" refer to a mixture of components that, when mixed together and subjected to polymerization conditions, result in the formation of a polymer network (such as a conventional or silicone hydrogel), as well as biomedical devices, ophthalmic devices, and contact lenses made therefrom. The reactive mixture may include reactive components such as monomers, macromers, prepolymers, crosslinkers, and initiators; wetting agents, polymers; additives such as dyes; light-absorbing compounds such as UV absorbers, pigments, photochromic compounds; pharmaceutical compounds; and / or nutraceutical compounds, all of which may be polymerizable or non-polymerizable but capable of being retained in the resulting biomedical device (e.g., a contact lens). The reactive mixture may also contain other components, such as diluents, that are intended to be removed from the device prior to use. It will be understood that a wide range of additives may be added depending on the contact lens being produced and its intended use. The concentrations of the components of the reactive mixture are expressed as weight percentages of all reactive components in the reactive mixture, and therefore exclude diluents. When diluents are used, their concentrations are expressed as weight percentages based on the amounts of all components (including the diluent) in the reactive mixture.

[0047] The term "silicone hydrogel contact lenses" refers to hydrogel contact lenses made from at least one silicone-containing component. Silicone hydrogel contact lenses typically have increased oxygen permeability compared to traditional hydrogels. Silicone hydrogel contact lenses utilize both their water content and polymer content to deliver oxygen to the eye.

[0048] The term "multifunctional" refers to a component having two or more polymerizable groups. The term "monofunctional" refers to a component having one polymerizable group.

[0049] The term "halogen" or "halo" refers to fluorine, chlorine, bromine, and iodine.

[0050] "Alkyl" means an optionally substituted straight or branched chain alkyl group containing the specified number of carbon atoms. If no number is specified, the alkyl (including any optional substituents on the alkyl) may contain 1 to 16 carbon atoms. Preferably, the alkyl group contains 1 to 10 carbon atoms, alternatively 1 to 8 carbon atoms, alternatively 1 to 6 carbon atoms, or alternatively 1 to 4 carbon atoms. Examples of alkyl include methyl, ethyl, propyl, isopropyl, butyl, iso-, sec-, and tert-butyl, pentyl, hexyl, heptyl, 3-ethylbutyl, and the like. Examples of substituents on alkyl include one, two, or three groups independently selected from hydroxy, amino, amido, oxa, carboxy, alkylcarboxy, carbonyl, alkoxy, thioalkyl, carbamate, carbonate, halogen, phenyl, benzyl, and combinations thereof. "Alkylene" refers to a divalent alkyl group, such as -CH2-, -CH2CH2-, -CH2CH2CH2-, -CH2CH(CH3)CH2-, and -CH2CH2CH2CH2-.

[0051] "Haloalkyl" means an alkyl group as defined above substituted with one or more halogen atoms, each halogen independently being F, Cl, Br, or I. A preferred halogen is F. Preferred haloalkyl groups contain 1 to 6 carbons, more preferably 1 to 4 carbons, and even more preferably 1 to 2 carbons. "Haloalkyl" includes perhaloalkyl groups such as -CF3- or -CF2CF3-. "Haloalkylene" means a divalent haloalkyl group such as -CH2CF2-.

[0052] "Cycloalkyl" refers to an optionally substituted cyclic hydrocarbon containing the specified number of ring carbon atoms. If no number is specified, the cycloalkyl may contain 3 to 12 ring carbon atoms. Preferred are C3-C8 cycloalkyl groups, C3-C7 cycloalkyl, more preferably C4-C7 cycloalkyl, and even more preferably C5-C6 cycloalkyl. Examples of cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. Examples of substituents on cycloalkyl include one, two, or three groups independently selected from alkyl, hydroxy, amino, amido, oxa, carbonyl, alkoxy, thioalkyl, amido, carbamate, carbonate, halo, phenyl, benzyl, and combinations thereof. "Cycloalkylene" refers to a divalent cycloalkyl group such as 1,2-cyclohexylene, 1,3-cyclohexylene, or 1,4-cyclohexylene.

[0053] "Heterocycloalkyl" means a cycloalkyl ring or ring system, as defined above, in which at least one ring carbon is replaced with a heteroatom selected from nitrogen, oxygen, and sulfur. The heterocycloalkyl ring is optionally fused or otherwise attached to other heterocycloalkyl rings and / or non-aromatic hydrocarbon rings and / or phenyl rings. Preferred heterocycloalkyl groups have 5 to 7 members. More preferred heterocycloalkyl groups have 5 or 6 members. Heterocycloalkylene means a divalent heterocycloalkyl group.

[0054] "Aryl" refers to an optionally substituted aromatic hydrocarbon ring system containing at least one aromatic ring. The aryl group contains the specified number of ring carbon atoms. If no number is specified, the aryl may contain 6 to 14 ring carbon atoms. The aromatic ring may be optionally fused to or otherwise attached to other aromatic or non-aromatic hydrocarbon rings. Examples of aryl groups include phenyl, naphthyl, and biphenyl. Preferred examples of aryl groups include phenyl. Examples of substituents on aryl groups include one, two, or three groups independently selected from alkyl, hydroxy, amino, amido, oxa, carboxy, alkylcarboxy, carbonyl, alkoxy, thioalkyl, carbamate, carbonate, halo, phenyl, benzyl, and combinations thereof. "Arylene" refers to a divalent aryl group, such as 1,2-phenylene, 1,3-phenylene, or 1,4-phenylene.

[0055] "Heteroaryl" refers to an aryl ring or ring system, as defined above, in which at least one ring carbon atom is replaced with a heteroatom selected from nitrogen, oxygen, and sulfur. The heteroaryl ring may be fused to or otherwise bonded to one or more heteroaryl rings, aromatic or non-aromatic hydrocarbon rings, or heterocycloalkyl rings. Examples of heteroaryl groups include pyridyl, furyl, and thienyl. "Heteroarylene" refers to a divalent heteroaryl group.

[0056] "Alkoxy" means an alkyl group attached to the parent molecular moiety through an oxygen bridge. Examples of alkoxy groups include, for example, methoxy, ethoxy, propoxy, and isopropoxy. "Thioalkyl" means an alkyl group attached to the parent molecular moiety through a sulfur bridge. Examples of thioalkyl groups include, for example, methylthio, ethylthio, n-propylthio, and isopropylthio. "Aryloxy" means an aryl group attached to the parent molecular moiety through an oxygen bridge. An example is phenoxy. "Cyclicalkoxy" means a cycloalkyl group attached to the parent moiety through an oxygen bridge.

[0057] "Alkylamine" means an alkyl group attached to the parent molecular moiety through an --NH bridge. Alkyleneamine means a divalent alkylamine group, such as --CH.sub.2CH.sub.2NH--.

[0058] "Siloxanyl" refers to a structure having at least one Si-O-Si bond. Thus, for example, a siloxanyl group refers to a group having at least one Si-O-Si group (i.e., a siloxane group), and a siloxanyl compound refers to a compound having at least one Si-O-Si group. "Siloxanyl" refers to monomers (e.g., Si-O-Si) as well as oligomeric / polymeric structures (e.g., -[Si-O] n - (where n is 2 or greater). Each silicon atom in the siloxanyl group is independently selected to complete their valence. A group (where R A is as defined in options (b) to (i) of Formula A).

[0059] "Silyl" means a structure of the formula R3Si-, and "siloxy" means a structure of the formula R3Si-O-, where each R in silyl or siloxy is independently selected from trimethylsiloxy, C1-C8 alkyl (preferably C1-C3 alkyl, more preferably ethyl or methyl), and C3-C8 cycloalkyl.

[0060] "Alkyleneoxy" refers to a group having the general formula -(alkylene-O) p -or -(O-alkylene) p -, where alkylene is as defined above, p is 1 to 200, or 1 to 100, or 1 to 50, or 1 to 25, or 1 to 20, or 1 to 10, and each alkylene is independently optionally substituted with one or more groups independently selected from hydroxyl, halo (e.g., fluoro), amino, amido, ether, carbonyl, carboxyl, and combinations thereof. When p is greater than 1, each alkylene may be the same or different, and the alkyleneoxy may be in a block or random configuration. When the alkyleneoxy forms a terminal group in a molecule, the terminal end of the alkyleneoxy may be, for example, a hydroxy or alkoxy (e.g., HO-[CHCHO] p - or CHO-[CHCHO] p Examples of alkyleneoxy include polyethyleneoxy, polypropyleneoxy, polybutyleneoxy, and poly(ethyleneoxy-co-propyleneoxy).

[0061] "Oxaalkylene" means an alkylene group as defined above in which one or more non-adjacent CH groups is replaced with an oxygen atom, such as -CHCHOCH(CH)CH-. "Thiaalkylene" means an alkylene group as defined above in which one or more non-adjacent CH groups is replaced with a sulfur atom, such as -CHCHSCH(CH)CH-.

[0062] The term "linking group" refers to a moiety that connects a polymerizable group to a parent molecule. The linking group may be any moiety that is compatible with the compound of which it is a part, does not undesirably interfere with the polymerization of the compound, and is stable under the conditions of polymerization, as well as under the conditions of processing and storage of the final product. For example, the linking group may be a bond or may include one or more alkylene, haloalkylene, amide, amine, alkyleneamine, carbamate, ester (-CO-), arylene, heteroarylene, cycloalkylene, heterocycloalkylene, alkyleneoxy, oxaalkylene, thiaalkylene, haloalkyleneoxy (alkyleneoxy substituted with one or more halo groups, e.g., -OCF-, -OCFCF-, -OCFCH-), siloxanyl, alkylenesiloxanyl, or combinations thereof. The linking group may be optionally substituted with one or more substituents. Suitable substituents may include those independently selected from alkyl, halo (e.g., fluoro), hydroxyl, HO-alkyleneoxy, MeO-alkyleneoxy, siloxanyl, siloxy, siloxy-alkyleneoxy-, siloxy-alkylene-alkyleneoxy- (two or more alkyleneoxy groups may be present, and each methylene in the alkylene and alkyleneoxy is independently optionally substituted with hydroxyl), ether, amine, carbonyl, carbamate, and combinations thereof. The linking group may also be substituted with a polymerizable group (in addition to the polymerizable group to which it is attached) such as (meth)acrylate.

[0063] Preferred linking groups include C1-C8 alkylene (preferably C2-C6 alkylene) and C1-C8 oxaalkylene (preferably C2-C6 oxaalkylene), each of which is optionally substituted with one or two groups independently selected from hydroxyl and siloxy. Preferred linking groups also include carboxylate, amide, C1-C8 alkylene-carboxylate-C1-C8 alkylene, or C1-C8 alkylene-amide C1-C8 alkylene.

[0064] When the linking group is composed of a combination of the above moieties (e.g., alkylene and cycloalkylene), the moieties may be present in any order. For example, in Formula A below, if L is shown to be -alkylene-cycloalkylene-, then Rg-L may be either Rg-alkylene-cycloalkylene- or Rg-cycloalkylene-alkylene-. Regardless, the listed order represents the preferred order in which the moieties appear in the compound, starting from the terminal polymerizable group (Rg or Pg) to which the linking group is attached. For example, in Formula A, if L is shown to be alkylene-cycloalkylene, then Rg-L is preferably Rg-alkylene-cycloalkylene-.

[0065] The term "electron-withdrawing group" (EWG) refers to a chemical group that withdraws electron density from the atom or group of atoms to which it is bonded. Examples of EWGs include, but are not limited to, cyano, amide, ester, keto, or aldehyde. A preferred EWG is cyano (CN).

[0066] The term "light absorbing compound" refers to a chemical that absorbs light within the visible spectrum (e.g., in the range of 380 nm to 780 nm). A "high-energy radiation absorber," "UV / HEV absorber," or "high-energy light absorbing compound" is a chemical that absorbs various wavelengths of ultraviolet radiation, high-energy visible light, or both. The ability of a material to absorb light of a particular wavelength can be determined by measuring its ultraviolet / visible transmission or absorption spectrum.

[0067] When compounds described herein contain olefinic double bonds or other centers of geometric asymmetry, unless otherwise indicated, the compounds are intended to include the cis, trans, Z-, and E-configurations, as well as all tautomeric and salt forms.

[0068] The term "optional substituent" means that a hydrogen atom of the underlying moiety is optionally replaced by a substituent. Any substituent that is sterically practical at the substitution site and synthetically feasible may be used. Identification of suitable optional substituents is well within the ability of one of ordinary skill in the art. Examples of "optional substituents" include, but are not limited to, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 thioalkyl, C3-C7 cycloalkyl, aryl, halo, hydroxy, amino, NR 4 R 5 , benzyl, SO3H, SO3Na, or -YP g In the formula, R 4 and R 5 are independently H or C1-C6 alkyl, Y is a linking group, and P g is a polymerizable group. The aforementioned substituents may be optionally substituted with optional substituents (preferably not further substituted unless otherwise specified). For example, alkyl may be substituted with halo (e.g., as in CF).

[0069] "Substructure" means the chemical structure of any compound derived from that chemical structure through the replacement of one or more hydrogen atoms by any other atom (wherein the atom may be bonded to other atoms or groups). The replacement may be, for example, one or more, preferably one or two, more preferably one hydrogen atom with an independently selected optional substituent. Included within the definition of "substructure" are materials from which the substructure forms a fragment of a larger compound, such as a monomer, polymer, or macromolecule (e.g., containing one or more polymerizable groups).

[0070] "Visible light absorption maximum" means the wavelength in the visible light wavelength range (380 nm to 760 nm) at which the absorbance of light is greatest. The definition includes materials that exhibit absorption maxima outside the visible light range, such as in the UV region.

[0071] The term "photostable," "photostability," or similar expressions means that a compound (which, when measured, may be optionally embedded in an ophthalmic device such as a hydrogel contact lens, optionally measured either inside or outside a blister pack or vial) exhibits a loss of 20 percent or less of absorbance at its visible light absorption maximum after exposure to light under conditions such as those of the International Conference on Harmonisation (ICH) Technical Requirements for Registration of Pharmaceuticals for Human Use guideline, Q1B, Photostability Testing of New Drug Substances and Products, published November 1996. Preferably, the exposure is at least 1.5192 x 10 6 Estimated illuminance exposure in lux hours (168.8 hours exposure time) and 259.4 watt-hours / m 2 The test is performed under ICH photostability guidelines, preferably in a photostability chamber controlled at 25°C / Amb RH, using an Option 2 light source with an estimated UV radiation exposure of 16.2 hours (exposure time). After exposure, a UV / visible spectrum of the sample is collected and compared to the spectrum of the sample before exposure. As an example, if the absorbance at the visible light absorption maximum before exposure is 4 absorbance units and after exposure is 2 absorbance units, the loss of absorbance is 50 percent. In the present invention, the loss of absorbance after exposure is preferably 15 percent or less, or 10 percent or less, or 5 percent or less, or 4 percent or less, or 3 percent or less, or 2 percent or less, or 1 percent or less, or 0.5 percent or less, or 0.1 percent or less.

[0072] The term "more photostable than macular pigment" or similar expression means that the compound (which, when tested, may be optionally embedded in an ophthalmic device such as a hydrogel contact lens and optionally measured either inside or outside a blister pack) exhibits less loss of absorbance at the visible light absorption maximum after exposure to light under the ICH photostability guidelines, as described above, than is observed in macular pigment.

[0073] The term full width at half maximum (FWHM) refers to the width of an absorbance peak at half its maximum intensity.

[0074] Unless otherwise stated, ratios, percentages, parts, etc. are by weight.

[0075] Unless otherwise specified, numerical ranges, such as in "from 2 to 10" or "between 2 and 10," are inclusive of the numbers defining the range (e.g., 2 and 10).

[0076] As noted above, in one aspect, the present invention provides compounds that substantially mimic the visible light absorption characteristics of macular pigment. The compounds are more photostable than macular pigment and therefore can be used to manufacture products. For example, the compounds may be used in ophthalmic devices.

[0077] Thus, the compounds of the present invention may have a visible light absorption maximum of 430 nm to 480 nm and a full width at half maximum (FWHM) at the visible light absorption maximum of at least 35 nm and at most 100 nm. The compounds may be photostable (e.g., as measured according to ICH guideline Q1B). The compounds may be more photostable than macular pigment.

[0078] The compound may have a visible light absorption maximum of 440 nm to 470 nm, or 445 nm to 465 nm, or 450 nm to 460 nm, or 455 nm to 460 nm.

[0079] The compounds may exhibit a FWHM at their visible absorption maximum of at least 35 nm, or at least 40 nm, or at least 45 nm, or at least 55 nm, or at least 60 nm, or at least 65 nm. The compounds may exhibit a FWHM at their visible absorption maximum of at most 95 nm, or at most 90 nm, or at most 85 nm, or at most 80 nm, or at most 75 nm, or at most 70 nm. The FWHM at their visible absorption maximum may be in the range of 35 nm to 100 nm, or 45 nm to 90 nm, or 55 nm to 80 nm, or 60 nm to 75 nm, or 65 nm to 70 nm.

[0080] The compounds of the invention may exhibit a molar extinction coefficient at the visible light absorption maximum of at least 5000, or at least 5500, or at least 6000, or at least 6500, or at least 7000, or at least 7500.

[0081] The compounds of the present invention may include a chromophore having a substructure of formula I:

[0082] [ka] wherein EWG at each occurrence is independently an electron-withdrawing group, and the compound exhibits a visible light absorbance peak in the range of 440 nm to 480 nm.

[0083] The EWG, at each occurrence, may independently be cyano, amide, ester, keto, or aldehyde. Preferably, the EWG, at each occurrence, is cyano.

[0084] The compound of the invention may be of formula II:

[0085] [ka] wherein EWG in each occurrence is independently an electron withdrawing group, n is 1, 2, or 3, and R 1is independently in each occurrence H, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 thioalkyl, C3-C7 cycloalkyl, aryl, halo, hydroxy, amino, NR 3 R 4 , benzyl, SO3H, or SO3M (where M is a monovalent cation such as sodium or potassium), or -YP g and R 3 and R 4 are independently H or C1-C6 alkyl, Y is a linking group, and P g is a polymerizable group. Preferably, the compound is 0, 1, or 2-YP g When n in formula II is 2 or 3, R 1 The group may be located at any substitutable position on the ring.

[0086] Compounds of formula II are those in which R 1 are independently H, or C1-C6 alkyl (preferably ethyl or methyl).

[0087] The chromophore of formula II is where n is 1 and R 1 YP g The compound may include a compound of formula II-2, which is a compound of formula II, wherein:

[0088] Compounds of formula II and II-2 are represented by the formula: g The compound of formula II-3 may be a compound of formula II or II-2, where the (polymerizable group) is independently styryl, vinyl carbonate, vinyl ether, vinyl carbamate, N-vinyl lactam, N-vinyl amide, (meth)acrylate, or (meth)acrylamide. Preferred polymerizable groups include (meth)acrylate or (meth)acrylamide. More preferred polymerizable groups are methacrylate.

[0089] Compounds of formula II, II-2, and II-3 may include compounds of formula II-4, which are compounds of formula II, II-2, or II-3 where Y (the linking group) in each occurrence is independently alkylene, cycloalkylene, heterocycloalkylene, arylene (e.g., phenylene), heteroarylene, oxaalkylene, alkylene-amido-alkylene, alkylene-amine-alkylene, or a combination of any of the foregoing groups. Preferred linking groups include C1-C8 alkylene (e.g., ethylene or propylene), C1-C8 oxaalkylene, C1-C8 alkylene-amido-C1-C8 alkylene, and C1-C8 alkylene-amine-C1-C8 alkylene. Particularly preferred is C1-C8 oxaalkylene, or C2-C4 oxaalkylene, or oxaethylene (—O—CH2CH2—).

[0090] Compounds of formula II, II-1, II-2, II-3, and II-4 may include compounds of formula II-5, which are compounds of formula II, II-1, II-2, II-3, or II-4 where EWG at each occurrence is independently cyano, amide, ester, keto, or aldehyde. EWG at each occurrence may be cyano.

[0091] Compounds of formula II, II-1, II-2, II-3, II-4, and II-5 may include compounds of formula II-6, which are compounds of formula II, II-1, II-2, II-3, II-4, or II-5 where n is 1 or 2, preferably n is 1.

[0092] The compounds of the invention may be of formula III:

[0093] [ka] wherein EWG in each occurrence is independently an electron-withdrawing group; R 1 is H, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 thioalkyl, C3-C7 cycloalkyl, aryl, halo, hydroxy, amino, NR 3 R4 , benzyl, SO3H, or SO3M (where M is a monovalent cation such as sodium or potassium), or YP g and R 3 and R 4 are independently H or C1 to C6 alkyl, Y is a linking group, and Pg is a polymerizable group.

[0094] The compound of formula III is R 1 is H, or C1-C6 alkyl (preferably ethyl or methyl).

[0095] The chromophore of formula III is R 1 YP g The compound may include a compound of formula III-2, which is a compound of formula III, wherein:

[0096] The compounds of formula III and III-2 are P g The compound of formula III-3 may be a compound of formula III or III-2, in which the (polymerizable group) comprises styryl, vinyl carbonate, vinyl ether, vinyl carbamate, N-vinyl lactam, N-vinyl amide, (meth)acrylate, or (meth)acrylamide. Preferred polymerizable groups include (meth)acrylate or (meth)acrylamide. More preferred polymerizable groups are methacrylate.

[0097] Compounds of formula III, III-2, and III-3 may include compounds of formula III-4, which are compounds of formula III, III-2, or III-3 where Y (the linking group) is alkylene, cycloalkylene, heterocycloalkylene, arylene (e.g., phenylene), heteroarylene, oxaalkylene, alkylene-amide-alkylene, alkylene-amine-alkylene, or any combination of these groups. Preferred linking groups include C1-C8 alkylene (e.g., ethylene or propylene), C1-C8 oxaalkylene, C1-C8 alkylene-amide-C1-C8 alkylene, and C1-C8 alkylene-amine-C1-C8 alkylene. Particularly preferred are C1-C8 oxaalkylene, C2-C4 oxaalkylene, or oxaethylene (—O—CH2CH2—).

[0098] Compounds of formula III, III-1, III-2, III-3, and III-4 may include compounds of formula III-5, which are compounds of formula III, III-1, III-2, III-3, or III-4 where the EWG at each occurrence is independently cyano, amide, ester, keto, or aldehyde. The EWG at each occurrence may be cyano.

[0099] Specific examples of compounds of the present invention are shown in Table A.

[0100] [Table 1]

[0101] The compounds of the present invention can be used in combination with other light-absorbing compounds to provide desirable absorption properties. For example, a preferred composition may include the above-mentioned compounds together with a UV-absorbing compound. Suitable UV-absorbing compounds are well known in the art and fall into several categories, including, but not limited to, benzophenones, benzotriazoles, triazines, substituted acrylonitriles, salicylic acid derivatives, benzoic acid derivatives, cinnamic acid derivatives, chalcone derivatives, dipnone derivatives, crotonic acid derivatives, or any mixture thereof. A preferred class of UV-absorbing compounds is benzotriazoles, such as Norbloc (2-(2'-hydroxy-5-methacrylyloxyethylphenyl)-2H-benzotriazole).

[0102] The compounds of the present invention may be included in reactive mixtures to form a variety of products, including biomedical and ophthalmic devices. The compounds may, for example, be incorporated into the device and / or coated onto the surface of the device. When incorporated into a device, the compounds may generally be added to the reactive mixture from which the device is made and may be present in any amount up to their solubility limits. For example, the compounds may be present in a concentration of at least 0.1 percent, or at least 2 percent, and up to 10 percent or up to 5 percent, based on the weight percentage of all components in the reactive mixture excluding the diluent. Typical concentrations may range from 1 to 5%. The upper limit is typically determined by the solubility of the compound with other comonomers and / or diluents in the reactive monomer mixture.

[0103] Preferably, the compounds of the present invention are contained in ophthalmic devices. Various ophthalmic devices may be made, including eyeglasses, sunglasses, hard contact lenses, soft contact lenses, corneal onlays, corneal inlays, intraocular lenses, or overlay lenses. Preferably, the ophthalmic device is an intraocular lens or a soft contact lens. Soft contact lenses may be made from conventional (non-silicone) hydrogels or silicone hydrogels.

[0104] The ophthalmic devices of the present invention may comprise the free radical reaction product of a reactive mixture containing one or more monomers (also referred to herein as device-forming monomers or hydrogel-forming monomers) suitable for making the desired ophthalmic device, and any optional components. When polymerized, the reactive mixture results in the formation of a polymer network in which the ophthalmic device may be included. The polymer network may be, for example, a hydrogel (e.g., a conventional hydrogel or a silicone hydrogel).

[0105] The compounds of the present invention may be copolymerized with other components in a reactive mixture, in which case the reactive mixture may contain one or more of the compounds of the present invention in addition to one or more monomers suitable for making the desired ophthalmic device (and any components).

[0106] Non-limiting examples of polymer networks into which the compounds of the invention may be incorporated (e.g., as monomers) are described above, and include, for example, etafilcon, genfilcon, hilafilcon, lenefilcon, nesofilcon, omafilcon, polymacon, vifilcon, acquafilcon, asmofilcon, balafilcon, comfilcon, and the like. Examples of seroconazole include comfilcon, delefilcon, enfilcon, fanfilcon, formofilcon, galyfilcon, lotrafilcon, narafilcon, riofilcon, samfilcon, senofilcon, somofilcon, and stenfilcon, including all variants thereof.

[0107] As a further example, the polymer network may be made from a reactive mixture including one or more of a hydrophilic component, a hydrophobic component, a silicon-containing component, a polyamide, a wetting agent such as a crosslinker, and additional components such as a diluent and an initiator. As noted above, the reactive mixture may also contain one or more compounds of the present invention.

[0108] hydrophilic component Examples of suitable families of hydrophilic monomers that may be present in the reactive mixture include (meth)acrylates, styrenes, vinyl ethers, (meth)acrylamides, N-vinyl lactams, N-vinyl amides, N-vinyl imides, N-vinyl ureas, O-vinyl carbamates, O-vinyl carbonates, other hydrophilic vinyl compounds, and mixtures thereof.

[0109] Non-limiting examples of hydrophilic (meth)acrylate and (meth)acrylamide monomers include acrylamide, N-isopropylacrylamide, N,N-dimethylaminopropyl(meth)acrylamide, N,N-dimethylacrylamide (DMA), 2-hydroxyethyl methacrylate (HEMA), 2-hydroxypropyl(meth)acrylate, 3-hydroxypropyl(meth)acrylate, 2,3-dihydroxypropyl(meth)acrylate, 2-hydroxybutyl(meth)acrylate, 3-hydroxybutyl(meth)acrylate, 4-hydroxybutyl(meth)acrylate, N-(2-hydroxyethyl)(meth)acrylamide, N,N-bis(2-hydroxyethyl)(meth)acrylamide, N-(2-hydroxypropyl)(meth)acrylamide, N,N-bis(2-hydroxypropyl)(meth)acrylamide, N-(3-hydroxypropyl)(meth)acrylamide, N-hydroxypropyl)(meth)acrylamide, N-(2-hydroxybutyl)(meth)acrylamide, N-(3-hydroxybutyl)(meth)acrylamide, N-(4-hydroxybutyl)(meth)acrylamide, 2-aminoethyl(meth)acrylate, 3-aminopropyl(meth)acrylate, 2-aminopropyl(meth)acrylate, N-2-aminoethyl(meth)acrylamide), N-3-aminopropyl(meth)acrylamide, N-2-aminopropyl(meth)acrylamide, N,N-bis-2-aminoethyl(meth)acrylamide, N,N-bis-3-aminopropyl(meth)acrylamide, N,N-bis-2-aminopropyl(meth)acrylamide, glycerol methacrylate, polyethylene glycol monomethacrylate, (meth)acrylic acid, vinyl acetate, acrylonitrile, and mixtures thereof.

[0110] The hydrophilic monomers may also be ionic, such as anionic, cationic, zwitterionic, betaine, and mixtures thereof. Non-limiting examples of such charged monomers include (meth)acrylic acid, N-[(ethenyloxy)carbonyl]-β-alanine (VINAL), 3-acrylamidopropanoic acid (ACA1), 5-acrylamidopropanoic acid (ACA2), 3-acrylamido-3-methylbutanoic acid (AMBA), 2-(methacryloyloxy)ethyltrimethylammonium chloride (Q salt or METAC), 2-acrylamido-2-methylpropanesulfonic acid (AMPS), 1-propanaminium, N-(2-carboxyethyl)-N,N-dimethyl-3-[(1-oxo-2-propen-1-yl)amino]-, inner salt (CBT), 1-propanaminium, N,N-dimethyl-N-[3-[(1-oxo-2-propen-1-yl)amino]propyl]-3-sulfo-, inner salt (SBT), 3,5-dioxa- Examples include 8-aza-4-phosphanundec-10-ene-1-aminium, 4-hydroxy-N,N,N-trimethyl-9-oxo-, inner salt, 4-oxide (9CI) (PBT), 2-methacryloyloxyethyl phosphorylcholine, 3-(dimethyl(4-vinylbenzyl)ammonio)propane-1-sulfonate (DMVBAPS), 3-((3-acrylamidopropyl)dimethylammonio)propane-1-sulfonate (AMPDAPS), 3-((3-methacrylamidopropyl)dimethylammonio)propane-1-sulfonate (MAMPDAPS), 3-((3-(acryloyloxy)propyl)dimethylammonio)propane-1-sulfonate (APDAPS), and methacryloyloxy)propyl)dimethylammonio)propane-1-sulfonate (MAPDAPS).

[0111] Non-limiting examples of hydrophilic N-vinyl lactam and N-vinyl amide monomers include N-vinylpyrrolidone (NVP), N-vinyl-2-piperidone, N-vinyl-2-caprolactam, N-vinyl-3-methyl-2-caprolactam, N-vinyl-3-methyl-2-piperidone, N-vinyl-4-methyl-2-piperidone, N-vinyl-4-methyl-2-caprolactam, N-vinyl-3-ethyl-2-pyrrolidone, N-vinyl-4,5-dimethyl-2-pyrrolidone, N-vinylacetamide (NVA), N-vinyl-N-methylacetamide (VMA), N-vinyl-N-ethylacetamide, N-vinyl-N-ethylformamide, N-vinylformamide, N-vinyl-N-methylpropionamide, N-vinyl-N-methyl-2-methylpropionamide, N-vinyl ... N-methylpropionamide, N-vinyl-N,N'-dimethylurea, 1-methyl-3-methylene-2-pyrrolidone, 1-methyl-5-methylene-2-pyrrolidone, 5-methyl-3-methylene-2-pyrrolidone, 1-ethyl-5-methylene-2-pyrrolidone, N-methyl-3-methylene-2-pyrrolidone, 5-ethyl-3-methylene-2-pyrrolidone, 1-N-propyl-3-methylene-2-pyrrolidone, 1-N-propyl-5-methylene-2-pyrrolidone, 1-isopropyl-3-methylene-2-pyrrolidone, 1-isopropyl-5-methylene-2-pyrrolidone, N-vinyl-N-ethylacetamide, N-vinyl-N-ethylformamide, N-vinylformamide, N-vinylisopropylamide, N-vinylcaprolactam, N-vinylimidazole, and mixtures thereof.

[0112] Non-limiting examples of hydrophilic O-vinyl carbamate and O-vinyl carbonate monomers include N-2-hydroxyethyl vinyl carbamate and N-carboxy-β-alanine N-vinyl ester. Further examples of hydrophilic vinyl carbonate or vinyl carbamate monomers are disclosed in U.S. Patent No. 5,070,215. Hydrophilic oxazolone monomers are disclosed in U.S. Patent No. 4,910,277.

[0113] Other hydrophilic vinyl compounds include ethylene glycol vinyl ether (EGVE), di(ethylene glycol) vinyl ether (DEGVE), allyl alcohol, and 2-ethyloxazoline.

[0114] The hydrophilic monomer may also be a macromer or prepolymer of linear or branched poly(ethylene glycol), poly(propylene glycol), or statistical random or block copolymers of ethylene oxide and propylene oxide, having polymerizable moieties such as (meth)acrylate, styrene, vinyl ether, (meth)acrylamide, N-vinylamide, etc. Macromers of these polyethers have one polymerizable group, and prepolymers may have two or more polymerizable groups.

[0115] Preferred hydrophilic monomers of the present invention are DMA, NVP, HEMA, VMA, NVA, and mixtures thereof. Preferred hydrophilic monomers include mixtures of DMA and HEMA. Other suitable hydrophilic monomers will be apparent to those skilled in the art.

[0116] Generally, there are no particular limitations regarding the amount of hydrophilic monomer present in the reactive monomer mixture. The amount of hydrophilic monomer may be selected based on the desired properties of the resulting hydrogel, including water content, transparency, wettability, protein uptake, etc. Wettability may be measured by contact angle, with desirable contact angles being less than about 100°, less than about 80°, and less than about 60°. The hydrophilic monomer may be present in an amount ranging from about 0.1 to about 100 weight percent, alternatively from about 1 to about 80 weight percent, alternatively from about 5 to about 65 weight percent, alternatively from about 40 to about 60 weight percent, or alternatively from about 55 to about 60 weight percent, based on the total weight of the reactive components in the reactive monomer mixture.

[0117] Silicon-containing ingredients Silicon-containing components suitable for use in the present invention include one or more polymerizable compounds, each compound independently including at least one polymerizable group, at least one siloxane group, and one or more linking groups connecting the polymerizable group(s) to the siloxane group(s). The silicon-containing component may contain, for example, 1 to 220 siloxane repeating units, such as those defined below. The silicon-containing component may also contain at least one fluorine atom.

[0118] The silicon-containing component may comprise one or more polymerizable groups, as defined above, one or more optionally repeating siloxane units, and one or more linking groups connecting the polymerizable groups to the siloxane units. The silicon-containing component may comprise one or more polymerizable groups, one or more optionally repeating siloxane units, and one or more linking groups connecting the polymerizable groups to the siloxane units, which are independently (meth)acrylate, styryl, vinyl ether, (meth)acrylamide, N-vinyl lactam, N-vinyl amide, O-vinyl carbamate, O-vinyl carbonate, vinyl groups, or mixtures thereof.

[0119] The silicon-containing component may comprise, independently, one or more polymerizable groups that are (meth)acrylate, (meth)acrylamide, N-vinyl lactam, N-vinyl amide, styryl, or mixtures of the foregoing, one or more optionally repeating siloxane units, and one or more linking groups connecting the polymerizable groups to the siloxane units.

[0120] The silicon-containing component may independently comprise one or more polymerizable groups that are (meth)acrylate, (meth)acrylamide, or mixtures of the foregoing, one or more optionally repeating siloxane units, and one or more linking groups connecting the polymerizable groups to the siloxane units.

[0121] The silicon-containing component may include one or more polymerizable compounds of Formula A:

[0122] [ka] During the ceremony, At least one R A is the formula R g -L group, where R g is a polymerizable group, L is a linking group, and the remaining R A are each independently (a)R g -L-, (b) C1-C optionally substituted with one or more hydroxy, amino, amido, oxa, carboxy, alkylcarboxy, carbonyl, alkoxy, amido, carbamate, carbonate, halo, phenyl, benzyl, or combinations thereof. 16 Alkyl, (c) C3-C optionally substituted with one or more alkyl, hydroxy, amino, amido, oxa, carbonyl, alkoxy, amido, carbamate, carbonate, halo, phenyl, benzyl, or combinations thereof. 12 cycloalkyl, (d) C-C optionally substituted with one or more alkyl, hydroxy, amino, amido, oxa, carboxy, alkylcarboxy, carbonyl, alkoxy, amido, carbamate, carbonate, halo, phenyl, benzyl, or combinations thereof. 14 aryl groups, (e) halo, (f) alkoxy, cyclic alkoxy, or aryloxy; (g) siloxy, (h) alkyleneoxy-alkyl or alkoxy-alkyleneoxy-alkyl, such as polyethyleneoxyalkyl, polypropyleneoxyalkyl, or poly(ethyleneoxy-co-propyleneoxyalkyl); or (i) a monovalent siloxane chain comprising 1 to 100 siloxane repeat units optionally substituted with alkyl, alkoxy, hydroxy, amino, oxa, carboxy, alkylcarboxy, alkoxy, amido, carbamate, halo, or combinations thereof; n is understood to be 0 to 500, or 0 to 200, or 0 to 100, or 0 to 20, and when n is other than 0, n is understood to be a distribution having a mode equal to the indicated value. When n is 2 or more, the SiO units may be the same or different R A may carry substituents, different R A When substituents are present, the n groups may be in a random or block configuration.

[0123] In formula A, three R A may each contain a polymerizable group, alternatively two R A may each contain a polymerizable group, or alternatively one R A may contain a polymerizable group.

[0124] Examples of silicon-containing components suitable for use in the present invention include, but are not limited to, the compounds listed in Table B. When the compounds of Table B contain polysiloxane groups, the number of SiO repeat units in such compounds is preferably 3 to 100, more preferably 3 to 40, or even more preferably 3 to 20, unless otherwise specified.

[0125] [Table 2-1]

[0126] [Table 2-2]

[0127] Additional non-limiting examples of suitable silicon-containing components are listed in Table C. Unless otherwise specified, where applicable, j2 is preferably 1 to 100, more preferably 3 to 40, or even more preferably 3 to 15. In compounds containing j1 or j2, the sum of j1 and j2 is preferably 2 to 100, more preferably 3 to 40, or even more preferably 3 to 15.

[0128] [Table 3-1]

[0129] [Table 3-2]

[0130] Mixtures of silicon-containing components may also be used. For example, suitable mixtures may include, but are not limited to, mixtures of mono-(2-hydroxy-3-methacryloxypropyloxy)-propyl-terminated mono-n-butyl-terminated polydimethylsiloxanes (OH-mPDMS) with different molecular weights, such as a mixture of OH-mPDMS containing 4 and 15 repeating SiO units, mixtures of OH-mPDMS with different molecular weights (e.g., containing 4 and 15 repeating SiO units) and silicon-based crosslinkers such as bis-3-acryloxy-2-hydroxypropyloxypropyl polydimethylsiloxane (ac-PDMS), and mixtures of 2-hydroxy-3-[3-methyl-3,3-di(trimethylsiloxy)silylpropoxy]-propyl methacrylate (SiMAA) and mono-methacryloxypropyl-terminated mono-n-butyl-terminated polydimethylsiloxanes (mPDMS) such as mPDMS1000.

[0131] The silicon-containing component used in the present invention may have an average molecular weight of from about 400 to about 4000 daltons.

[0132] The silicon-containing component(s) may be present in an amount of up to about 95% by weight, or from about 10 to about 80% by weight, or from about 20 to about 70% by weight of the reactive mixture (excluding diluent), based on all reactive components.

[0133] polyamide The reactive mixture may include at least one polyamide. As used herein, the term "polyamide" refers to polymers and copolymers containing repeating units containing amide groups. Polyamides may include cyclic amide groups, acyclic amide groups, and combinations thereof, and may be any polyamide known to those skilled in the art. Acyclic polyamides include pendant acyclic amide groups that are capable of association with hydroxyl groups. Cyclic polyamides include cyclic amide groups that are capable of association with hydroxyl groups.

[0134] Examples of suitable acyclic polyamides include polymers and copolymers comprising repeating units of formulas G1 and G2.

[0135] [ka] In the formula, X is a direct bond, —(CO)—, or —(CONHR 44 )-, wherein R 44 is a C1-C3 alkyl group, and R 40 is H, a linear or branched, substituted or unsubstituted C1-C4 alkyl group, and R 41 is selected from H, a straight or branched chain, substituted or unsubstituted C1-C4 alkyl group, an amino group having up to 2 carbon atoms, an amido group having up to 4 carbon atoms, and an alkoxy group having up to 2 carbon atoms; R 42 is selected from H, a linear or branched, substituted or unsubstituted C1-C4 alkyl group, or methyl, ethoxy, hydroxyethyl, and hydroxymethyl; R 43 is H, a straight or branched chain, substituted or unsubstituted C1-C4 alkyl group, or is selected from methyl, ethoxy, hydroxyethyl, and hydroxymethyl; R 40 and R 41 the total number of carbon atoms in R is 8 or less, including 7, 6, 5, 4, 3, or less; 42 and R 43 The total number of carbon atoms in R is 8 or less, including 7, 6, 5, 4, 3, or less. 40 and R 41The total number of carbon atoms in R may be 6 or less, or 4 or less. 42 and R 43 The total number of carbon atoms in the alkyl group may be up to 6. As used herein, a substituted alkyl group includes an alkyl group substituted with an amine group, an amide group, an ether group, a hydroxyl group, a carbonyl group, or a carboxyl group, or a combination thereof.

[0136] R 40 and R 41 may be independently selected from H, a substituted or unsubstituted C1-C2 alkyl group, X may be a direct bond, and R 40 and R 41 may be independently selected from H, a substituted or unsubstituted C1-C2 alkyl group. 42 and R 43 may be independently selected from H, substituted or unsubstituted C1-C2 alkyl groups, methyl, ethoxy, hydroxyethyl, and hydroxymethyl.

[0137] The acyclic polyamides of the present invention may comprise a majority of repeating units of Formula LV or Formula LVI, or the acyclic polyamides may comprise at least 50 mol %, such as at least about 70 mol %, and at least 80 mol %, of repeating units of Formula G or Formula G1. Specific examples of repeating units of Formula G and Formula G1 include N-vinyl-N-methylacetamide, N-vinylacetamide, N-vinyl-N-methylpropionamide, N-vinyl-N-methyl-2-methylpropionamide, N-vinyl-2-methyl-propionamide, N-vinyl-N,N'-dimethylurea, N,N-dimethylacrylamide, methacrylamide, and repeating units derived from the acyclic amides of Formulas G2 and G3.

[0138] [ka]

[0139] Examples of suitable cyclic amides that can be used to form the cyclic polyamides include α-lactams, β-lactams, γ-lactams, δ-lactams, and ε-lactams. Examples of suitable cyclic polyamides include polymers and copolymers comprising repeating units of formula G4:

[0140] [ka] In the formula, R 45 is a hydrogen atom or a methyl group, f is a number from 1 to 10, and X is a direct bond, —(CO)—, or —(CONHR 46 )-, where R 46 is a C1-C3 alkyl group. In Formula LIX, f may be 8 or less, including 7, 6, 5, 4, 3, 2, or 1. In Formula G4, f may be 6 or less, including 5, 4, 3, 2, or 1. In Formula G4, f may be 2 to 8, including 2, 3, 4, 5, 6, 7, or 8. In Formula LIX, f may be 2 or 3. When X is a direct bond, f may be 2. In such cases, the cyclic polyamide may be polyvinylpyrrolidone (PVP).

[0141] The cyclic polyamides of the present invention may comprise 50 mol % or more of repeat units of formula G4, or the cyclic polyamides may comprise at least 50 mol % of repeat units of formula G4, such as at least 70 mol %, and at least 80 mol %.

[0142] Polyamides may also be copolymers containing both cyclic and non-cyclic amide repeating units. Additional repeating units may be formed from monomers selected from hydroxyalkyl (meth)acrylates, alkyl (meth)acrylates, other hydrophilic monomers, and siloxane-substituted (meth)acrylates. Any of the monomers listed as suitable hydrophilic monomers may be used as comonomers to form additional repeating units. Specific examples of additional monomers that may be used to form polyamides include 2-hydroxyethyl (meth)acrylate, vinyl acetate, acrylonitrile, hydroxypropyl (meth)acrylate, methyl (meth)acrylate, and hydroxybutyl (meth)acrylate, dihydroxypropyl (meth)acrylate, polyethylene glycol mono(meth)acrylate, and mixtures thereof. Ionic monomers may also be included.Examples of ionic monomers include (meth)acrylic acid, N-[(ethenyloxy)carbonyl]-β-alanine (VINAL, CAS# 148969-96-4), 3-acrylamidopropanoic acid (ACA1), 5-acrylamidopentanoic acid (ACA2), 3-acrylamido-3-methylbutanoic acid (AMBA), 2-(methacryloyloxy)ethyltrimethylammonium chloride (Q salt or METAC), 2-acrylamido-2-methylpropanesulfonic acid (AMPS), 1-propanaminium, N-(2-carboxyethyl)-N,N-dimethyl-3-[(1-oxo-2-propen-1-yl)amino]-, inner salt (CBT, carboxybetaine, CAS 79704-35-1), 1-propanaminium, N,N-dimethyl-N-[3-[(1-oxo-2-propen-1-yl)amino]propyl]-3-sulfo-, inner salt (SBT, sulfobetaine, CAS 80293-60-3), 3,5-dioxa-8-aza-4-phosphanundec-10-ene-1-aminium, 4-hydroxy-N,N,N-trimethyl-9-oxo-, inner salt, 4-oxide(9CI) (PBT, phosphobetaine, CAS 163674-35-9, 2-methacryloyloxyethyl phosphorylcholine, 3-(dimethyl(4-vinylbenzyl)ammonio)propane-1-sulfonate (DMVBAPS), 3-((3-acrylamidopropyl)dimethylammonio)propane-1-sulfonate (AMPDAPS), 3-((3-methacrylamidopropyl)dimethylammonio)propane-1-sulfonate (MAMPDAPS), 3-((3-(acryloyloxy)propyl)dimethylammonio)propane-1-sulfonate (APDAPS), methacryloyloxy)propyl)dimethylammonio)propane-1-sulfonate (MAPDAPS).

[0143] The reactive monomer mixture may include both acyclic polyamides and cyclic polyamides or copolymers thereof. The acyclic polyamide may be any of the acyclic polyamides or copolymers thereof described herein, and the cyclic polyamide may be any of the cyclic polyamides or copolymers thereof described herein. The polyamide may be selected from the group consisting of polyvinylpyrrolidone (PVP), polyvinylmethylacetamide (PVMA), polydimethylacrylamide (PDMA), polyvinylacetamide (PNVA), poly(hydroxyethyl(meth)acrylamide), polyacrylamide, and copolymers and mixtures thereof. The polyamide may be a mixture of PVP (e.g., PVP K90) and PVMA (e.g., PVMA having an M of about 570 KDa). w The compound may be a mixture of the compounds having the formula:

[0144] The total amount of all polyamides in the reactive mixture may be in the range of 1% to about 35% by weight, such as in the range of 1% to about 15% by weight, and in the range of about 5% to about 15% by weight, in all cases based on the total weight of the reactive components of the reactive monomer mixture.

[0145] Without being bound by theory, when used with silicone hydrogels, polyamides function as internal wetting agents. The polyamides of the present invention may be non-polymeric, in which case they are incorporated into the silicone hydrogel as a semi-interpenetrating network. The polyamides are encapsulated or physically held within the silicone hydrogel. Alternatively, the polyamides of the present invention may be polymeric, for example, as polyamide macromers or prepolymers, in which case they are covalently incorporated into the silicone hydrogel. Mixtures of polymeric and non-polymeric polyamides may also be used.

[0146] When a polyamide is incorporated into the reactive monomer mixture, the polyamide may have a weight average molecular weight of at least 100,000 daltons, greater than about 150,000 daltons, from about 150,000 to about 2,000,000 daltons, or from about 300,000 to about 1,800,000 daltons. High molecular weight polyamides may also be used if they are compatible with the reactive monomer mixture.

[0147] Crosslinking agent It is generally desirable to add one or more crosslinking agents, also referred to as crosslinking monomers, multifunctional macromers, and prepolymers, to the reactive mixture. The crosslinking agent may be selected from difunctional crosslinkers, trifunctional crosslinkers, tetrafunctional crosslinkers, and mixtures thereof, including silicon-containing and non-silicon-containing crosslinkers. Non-silicon-containing crosslinkers include ethylene glycol dimethacrylate (EGDMA), tetraethylene glycol dimethacrylate (TEGDMA), trimethylolpropane trimethacrylate (TMPTMA), triallyl cyanurate (TAC), glycerol trimethacrylate, methacryloxyethyl vinyl carbonate (HEMAVc), allyl methacrylate, methylenebisacrylamide (MBA), and polyethylene glycol dimethacrylate, where the polyethylene glycol has a molecular weight of up to about 5000 daltons. The crosslinking agent is used in the reactive mixture in conventional amounts, for example, from about 0.000415 to about 0.0156 moles per 100 grams of reactive formulation. Alternatively, if the hydrophilic monomer and / or silicon-containing component are multifunctional by molecular design or due to impurities, the addition of a crosslinker to the reactive mixture is optional. Examples of hydrophilic monomers and macromers that can act as crosslinkers and, if present, do not require the addition of an additional crosslinker to the reactive mixture include (meth)acrylate and (meth)acrylamide end-capped polyethers. Other crosslinkers will be known to those skilled in the art and may be used to make the silicone hydrogels of the present invention.

[0148] It may be desirable to select a crosslinker that has similar reactivity with one or more of the other reactive components in the formulation. In some cases, it may be desirable to select a mixture of crosslinkers with different reactivities to control some physical, mechanical, or biological properties of the resulting silicone hydrogel. The structure and morphology of the silicone hydrogel may also be affected by the diluent(s) and curing conditions used.

[0149] To further increase the modulus and maintain tensile strength, polyfunctional silicon-containing components, including macromers, crosslinkers, and prepolymers, may also be included. Silicon-containing crosslinkers may be used alone or in combination with other crosslinkers. An example of a silicon-containing component that can act as a crosslinker and, when present, does not require the addition of a crosslinking monomer to the reactive mixture is α,ω-bismethacryloylpropyl polydimethylsiloxane. Another example is bis-3-acryloxy-2-hydroxypropyloxypropyl polydimethylsiloxane (ac-PDMS).

[0150] Rigid chemical structures and crosslinkers with polymerizable groups capable of undergoing free radical polymerization may also be used. Non-limiting examples of suitable rigid structures include crosslinkers containing phenyl and benzyl rings, such as 1,4-phenylenediacrylate, 1,4-phenylenedimethacrylate, 2,2-bis(4-methacryloxyphenyl)-propane, 2,2-bis[4-(2-acryloxyethoxy)phenyl]propane, 2,2-bis[4-(2-hydroxy-3-methacryloxypropoxy)phenyl]propane, and 4-vinylbenzyl methacrylate, and combinations thereof. Rigid crosslinkers may be included in amounts of about 0.5 to about 15, or about 2 to 10, or 3 to 7, based on the total weight of all reactive components. The physical and mechanical properties of the silicone hydrogels of the present invention can be optimized for specific applications by adjusting the components in the reactive mixture.

[0151] Non-limiting examples of silicone crosslinkers also include the polyfunctional silicon-containing components set forth in Table D above.

[0152] Further components The reactive mixture may contain additional components such as, but not limited to, diluents, initiators, UV absorbers, visible light absorbers, photochromic compounds, pharmaceuticals, nutritional supplements, antimicrobial substances, colorants, pigments, copolymeric dyes, non-polymeric dyes, release agents, and combinations thereof.

[0153] Suitable types of diluents for the silicone hydrogel reactive mixture include alcohols having 2 to 20 carbon atoms, amides derived from primary amines having 10 to 20 carbon atoms, and carboxylic acids having 8 to 20 carbon atoms. Diluents can also be primary, secondary, and tertiary alcohols.

[0154] Generally, the reactive components are mixed in a diluent to form a reactive mixture. Suitable diluents are well known in the art. For silicone hydrogels, suitable diluents are disclosed in WO 03 / 022321 and U.S. Patent Application Publication No. 6,020,445, the disclosures of which are incorporated herein by reference.

[0155] Suitable diluent classes for silicone hydrogel reactive mixtures include alcohols having 2 to 20 carbon atoms, amides derived from primary amines having 10 to 20 carbon atoms, and carboxylic acids having 8 to 20 carbon atoms. Primary and tertiary alcohols may also be used. Preferred classes include alcohols having 5 to 20 carbon atoms and carboxylic acids having 10 to 20 carbon atoms.

[0156] Specific diluents that can be used include 1-ethoxy-2-propanol, diisopropylaminoethanol, isopropanol, 3,7-dimethyl-3-octanol, 1-decanol, 1-dodecanol, 1-octanol, 1-pentanol, 2-pentanol, 1-hexanol, 2-hexanol, 2-octanol, 3-methyl-3-pentanol, tert-amyl alcohol, tert-butanol, 2-butanol, 1-butanol, 2-methyl-2 ... Examples of suitable diluents include ethanol, 2-propanol, 1-propanol, ethanol, 2-ethyl-1-butanol, (3-acetoxy-2-hydroxypropyloxy)-propylbis(trimethylsiloxy)methylsilane, 1-tert-butoxy-2-propanol, 3,3-dimethyl-2-butanol, tert-butoxyethanol, 2-octyl-1-dodecanol, decanoic acid, octanoic acid, dodecanoic acid, 2-(diisopropylamino)ethanol, and mixtures thereof. Examples of amide diluents include N,N-dimethylpropionamide and dimethylacetamide.

[0157] Preferred diluents include 3,7-dimethyl-3-octanol, 1-dodecanol, 1-decanol, 1-octanol, 1-pentanol, 1-hexanol, 2-hexanol, 2-octanol, 3-methyl-3-pentanol, 2-pentanol, t-amyl alcohol, tert-butanol, 2-butanol, 1-butanol, 2-methyl-2-pentanol, 2-ethyl-1-butanol, ethanol, 3,3-dimethyl-2-butanol, 2-octyl-1-dodecanol, decanoic acid, octanoic acid, dodecanoic acid, mixtures thereof, and the like.

[0158] More preferred diluents include 3,7-dimethyl-3-octanol, 1-dodecanol, 1-decanol, 1-octanol, 1-pentanol, 1-hexanol, 2-hexanol, 2-octanol, 1-dodecanol, 3-methyl-3-pentanol, 1-pentanol, 2-pentanol, t-amyl alcohol, tert-butanol, 2-butanol, 1-butanol, 2-methyl-2-pentanol, 2-ethyl-1-butanol, 3,3-dimethyl-2-butanol, 2-octyl-1-dodecanol, and mixtures thereof.

[0159] When a diluent is present, there is generally no particular limit as to the amount of diluent present. When a diluent is used, the diluent may be present in an amount ranging from about 2 to about 70 weight percent, such as from about 5 to about 50 weight percent and from about 15 to about 40 weight percent, based on the total weight of the reactive mixture (including reactive and non-reactive formulations). Mixtures of diluents may also be used.

[0160] A polymerization initiator may be used in the reactive mixture, and may include at least one of those that generate free radicals at moderately high temperatures, such as lauryl peroxide, benzoyl peroxide, isopropyl percarbonate, azobisisobutyronitrile, and photoinitiator systems such as aromatic α-hydroxyketones, alkoxyoxybenzoins, acetophenones, acylphosphine oxides, bisacylphosphine oxides, and tertiary amines plus diketones, and mixtures thereof. Specific examples of photoinitiators include 1-hydroxycyclohexyl phenyl ketone, 2-hydroxy-2-methyl-1-phenyl-propan-1-one, bis(2,6-dimethoxybenzoyl)-2,4-4-trimethylpentylphosphine oxide (DMBAPO), bis(2,4,6-trimethylbenzoyl)-phenylphosphine oxide (Irgacure 819), 2,4,6-trimethylbenzyldiphenylphosphine oxide and 2,4,6-trimethylbenzoyldiphenylphosphine oxide, benzoin methyl ester, and a combination of camphorquinone and ethyl 4-(N,N-dimethylamino)benzoate.

[0161] Commercially available visible light initiator systems (manufactured by IGM Resins BV, The Netherlands) include Irgacure® 819, Irgacure® 1700, Irgacure® 1800, Irgacure® 819, Irgacure® 1850, and Lucrin® TPO initiators. Commercially available UV photoinitiators (manufactured by IGM Resins BV) include Darocur® 1173 and Darocur® 2959. These and other photoinitiators that can be used are described in Volume III, Photoinitiators for Free Radical Cationic & Anionic Photopolymerization, 2nd Edition by J.V. Crivello & K. Dietliker; edited by G. Bradley; John Wiley and Sons; New York; In 1998, the initiator was described. The initiator is used in the reactive mixture in an amount effective to initiate photopolymerization of the reactive mixture, for example, about 0.1 to about 2 parts by weight per 100 parts of the reactive monomer mixture. Polymerization of the reactive mixture can be initiated using heat, visible or ultraviolet light, or other means, appropriately selected depending on the polymerization initiator used. Alternatively, initiation can be carried out using an electron beam without a photoinitiator. However, if a photoinitiator is used, the preferred initiator is a bisacylphosphine oxide, such as bis(2,4,6-trimethylbenzoyl)-phenylphosphine oxide (Irgacure® 819) or a combination of 1-hydroxycyclohexyl phenyl ketone and bis(2,6-dimethoxybenzoyl)-2,4-4-trimethylpentylphosphine oxide (DMBAPO).

[0162] The reactive mixture for making the ophthalmic devices of the present invention may include, in addition to the compounds of the present invention, any of the polymerizable compounds and optional components described above.

[0163] The reactive mixture may include a compound of the present invention, such as a compound of Formula I, and a hydrophilic component.

[0164] The reactive mixture may include a compound of the invention, such as a compound of Formula I, and a hydrophilic component selected from DMA, NVP, HEMA, VMA, NVA, methacrylic acid, and mixtures thereof. Mixtures of HEMA and methacrylic acid are preferred.

[0165] The reactive mixture may include a compound of the present invention, such as a compound of Formula I, a hydrophilic component, and a silicon-containing component.

[0166] The reactive mixture may include a compound of the present invention, such as a compound of Formula I, a hydrophilic component selected from DMA, HEMA, and mixtures thereof, a silicon-containing component selected from 2-hydroxy-3-[3-methyl-3,3-di(trimethylsiloxy)silylpropoxy]-propyl methacrylate (SiMAA), mono-methacryloxypropyl-terminated mono-n-butyl-terminated polydimethylsiloxane (mPDMS), mono-(2-hydroxy-3-methacryloxypropyl)-propyl ether-terminated mono-n-butyl-terminated polydimethylsiloxane (OH-mPDMS), and mixtures thereof, and a wetting agent (preferably PVP or PVMA). For the hydrophilic component, a mixture of DMA and HEMA is preferred. For the silicon-containing component, a mixture of SiMAA and mPDMS is preferred.

[0167] The reactive mixture may include a compound of the invention, such as a compound of Formula I, a hydrophilic component including a mixture of DMA and HEMA, and a silicon-containing component including a mixture of OH-mPDMS having 2-20 repeating units (preferably a mixture of 4 and 15 repeating units). Preferably, the reactive mixture further includes a silicon-containing crosslinker, such as ac-PDMS. Also preferably, the reactive mixture includes a wetting agent (preferably DMA, PVP, PVMA, or a mixture thereof).

[0168] The reactive mixture comprises a compound of the invention, such as a compound of Formula I, from about 1 to about 15 weight percent of at least one polyamide (e.g., an acyclic polyamide, a cyclic polyamide, or a mixture thereof), at least one first monofunctional hydroxyl-substituted poly(disubstituted siloxane) having 4 to 8 siloxane repeat units (e.g., OH-mPDMS, where n is 4 to 8, preferably n is 4), and at least one second hydroxyl-substituted poly(disubstituted siloxane) that is a monofunctional hydroxyl-substituted poly(disubstituted siloxane) having 10 to 200, or 10 to 100, or 10 to 50, or 10 to 20 siloxane repeat units (e.g., OH-mPDMS, where n is 10 to 200, or 10 to 50, or 10 to 20). The composition may comprise a first monofunctional hydroxyl-substituted poly(disubstituted siloxane) having 10 to 200 or 10 to 100 siloxane repeat units (where n is 15), about 5 to about 35 weight percent of at least one hydrophilic monomer, and, optionally, a polyfunctional hydroxyl-substituted poly(disubstituted siloxane) (e.g., ac-PDMS) having 10 to 200 or 10 to 100 siloxane repeat units. Preferably, the first monofunctional hydroxyl-substituted poly(disubstituted siloxane) and the second hydroxyl-substituted poly(disubstituted siloxane) are present in concentrations to provide a ratio of weight percent of the first monofunctional hydroxyl-substituted poly(disubstituted siloxane) to weight percent of the second hydroxyl-substituted poly(disubstituted siloxane) of 0.4 to 1.3 or 0.4 to 1.0.

[0169] The reactive mixture may contain optional components such as, but not limited to, one or more initiators, internal wetting agents, crosslinkers, other UV or HEV absorbers, and diluents.

[0170] Curing of Hydrogels and Lens Fabrication The reactive mixture may be formed by any method known in the art, such as by shaking or stirring, and used to form a polymeric article or device by known methods. The reactive components are mixed together, either with or without a diluent, to form the reactive mixture.

[0171] For example, an ophthalmic device can be prepared by mixing the reactive components and optionally diluent(s) with a polymerization initiator and curing under appropriate conditions to form a product that can later be formed into a suitable shape by lathing, cutting, etc. Alternatively, the reactive mixture can be placed in a mold and then cured into a suitable article.

[0172] A method of making a molded ophthalmic device, such as a silicone hydrogel contact lens, may include preparing a reactive monomer mixture, transferring the reactive monomer mixture to a first mold, placing a second mold over the first mold filled with the reactive monomer mixture, and curing the reactive monomer mixture by free radical copolymerization to form a silicone hydrogel in the shape of a contact lens.

[0173] The reactive mixture may be cured via any known process for shaping reactive mixtures in the production of contact lenses, including rotational molding and static molding. Rotational molding processes are disclosed in U.S. Patent Nos. 3,408,429 and 3,660,545, and static molding processes are disclosed in U.S. Patent Nos. 4,113,224 and 4,197,266. The contact lenses of the present invention may also be formed by direct molding of silicone hydrogels, which is economical and allows for precise control of the final shape of the hydrated lens. In this method, the reactive mixture is placed into a mold having the shape of the desired final silicone hydrogel, and the reactive mixture is exposed to conditions that polymerize the monomers, thereby producing a polymer in the approximate shape of the desired final product.

[0174] After curing, the lens may be subjected to extraction to remove unreacted components and release the lens from the lens mold. Extraction may be performed using conventional extraction fluids, such as organic solvents such as alcohols, or may be extracted using aqueous solutions.

[0175] An aqueous solution is a solution containing water. The aqueous solution of the present invention may contain at least about 20% by weight water, or at least about 50% by weight water, or at least about 70% by weight water, or at least about 95% by weight water. The aqueous solution may also contain additional water-soluble ingredients, such as inorganic salts or release agents, wetting agents, slip agents, pharmaceutical ingredients, and nutritional supplements, or combinations thereof. A release agent is a compound or mixture of compounds that, when combined with water, reduces the time required to remove a contact lens from a mold when compared to the time required to remove a contact lens using an aqueous solution without the release agent. The aqueous solution may not require special handling, such as purification, recycling, or special disposal.

[0176] Extraction can be accomplished, for example, by immersing the lens in an aqueous solution or exposing the lens to a stream of aqueous solution. Extraction can also include, for example, one or more of: heating the aqueous solution; agitating the aqueous solution; increasing the concentration of a release agent in the aqueous solution to a level sufficient to cause lens release; mechanically or ultrasonically agitating the lens; and incorporating at least one filter aid or extraction aid into the aqueous solution to a concentration sufficient to facilitate adequate removal of unreacted components from the lens. The foregoing, with or without the addition of heat, vibration, or both, can be carried out in a batch or continuous process.

[0177] To facilitate leaching and demolding, it may be desirable to apply physical agitation. For example, the lens mold part to which the lens is attached can be vibrated or moved back and forth in the aqueous solution. Other methods may include passing ultrasound through the aqueous solution.

[0178] The lenses may be sterilized by well known means such as, but not limited to, high pressure steam treatment.

[0179] As noted above, preferred ophthalmic devices are contact lenses, more preferably soft hydrogel contact lenses. The transmission wavelengths and percentages described herein may be measured on lenses of various thicknesses, for example, using the methods described in the Examples. By way of example, preferred center thicknesses for measuring transmission spectra in soft contact lenses may be 80-100 micrometers, or 90-100 micrometers, or 90-95 micrometers. Typically, measurements may be taken at the center of the lens, using, for example, an instrument slit width of 4 nm.

[0180] Silicone hydrogel ophthalmic devices (e.g., contact lenses) according to the present invention preferably exhibit the following properties. All values ​​are preceded by "about," and the device can have any combination of the listed properties. Properties can be determined by methods known to those skilled in the art, for example, as described in U.S. Pregrant Publication No. 20180037690, which is incorporated herein by reference. Water concentration %: at least 20%, or at least 25% and at most 80%, or at most 70% Haze: 30% or less, or 10% or less Advancing dynamic contact angle (Wilhelmy plate method): 100° or less, or 80° or less, or 50° or less Tensile modulus (psi): 120 or less, or 80-120 Oxygen permeability (Dk, Barrer): at least 80, or at least 100, or at least 150, or at least 200 Elongation at break: at least 100 With regard to ionic silicone hydrogels, the following properties (in addition to those cited above) may also be preferred: Lysozyme uptake (μg / lens): at least 100, or at least 150, or at least 500, or at least 700 Polyquaternium 1 (PQ1) uptake (%): 15 or less, or 10 or less, or 5 or less The compounds of the present invention may be used with other products in addition to ophthalmic devices.For example, the compounds may be used in windows (e.g., vehicle or building windows), or optical instruments such as binoculars and cameras.In such uses, the compounds may be coated on the surface of the device, for example.To facilitate coating, the compounds may be dissolved in a solvent.

[0181] Some embodiments of the present invention will now be described in detail in the following examples. [Example]

[0182] Test Method The UV-visible spectra of compounds in solution were measured on a Perkin Elmer Lambda 45, Agilent Cary 6000i, or Ocean Optics QE65 PRO (DH-2000-BAL light source) UV / VIS scanning spectrometer. Prior to use, the instrument was allowed to thermally equilibrate for at least 30 minutes. For the Perkin Elmer instrument, the scan range was 200-800 nm, the scan speed was 960 nm per minute, the slit width was 4 nm, the mode was set to transmission or absorbance, and baseline correction was selected. For the Cary instrument, the scan range was 200-800 nm, the scan speed was 600 nm / min, the slit width was 2 nm, the mode was set to transmission or absorbance, and baseline correction was selected. For the Ocean Optics instrument, the scan range was 200-800 nm, the slit width was 10 μm, the mode was set to transmission or absorbance, and baseline correction was selected. Baseline correction was performed before analyzing samples using the autozero function.

[0183] The ultraviolet-visible spectra of partially formed contact lenses from the claimed compositions were measured using packing solutions on a Perkin Elmer Lambda 45 UV / VIS, Agilent Cary 6000i, or Ocean Optic UV / VIS scanning spectrometer. Prior to use, the instrument was allowed to thermally equilibrate for at least 30 minutes. Baseline correction was performed using a plastic two-piece lens holder and a cuvette containing the same solvent. These two-piece contact lens holders were designed to hold the sample in the quartz cuvette at the location traversed by the incident light beam. A reference cuvette also housed the two-piece holder. To ensure consistent sample thickness, all lenses were fabricated using the same mold. The central thickness of the contact lenses was measured using an electronic thickness gauge. The reported central thickness and transmittance spectral coefficients were obtained by averaging data from three individual lenses.

[0184] It is important to ensure that the exterior of the cuvette is completely clean and dry and that there are no air bubbles within the cuvette. Measurement reproducibility is improved if the reference cuvette and its lens holder remain constant and all samples use the same sample cuvette and its lens holder, ensuring that both cuvettes are properly inserted into the instrument.

[0185] The following abbreviations are used throughout the examples and figures and have the following meanings: L: Liters (plural) mL: milliliters (plural possible) Equiv. or eq.: equivalent weight kg: kilograms (plural possible) g: grams (plural) mg: milligrams (plural) mol: moles (plural possible) mmol: millimoles (plural possible) Da: Daltons or g / mol kDa: kilodalton or atomic mass unit equal to 1,000 daltons min: minutes (plural possible) μm: micrometer (plural possible) nm: nanometers (plural possible) 1 H NMR: Proton nuclear magnetic resonance spectroscopy UV-VIS: Ultraviolet-Visible Light Spectroscopy TLC: Thin Layer Chromatography BC: Back or base curve plastic mold FC: Front curve plastic molding mold PP: Polypropylene, a homopolymer of propylene TT: Tuftec (Asahi Kasei Chemicals), a hydrogenated styrene butadiene block copolymer Z: Zeonor (Nippon Zeon Co. Ltd.), a polycycloolefin thermoplastic polymer DMA: N,N-dimethylacrylamide (Jarchem) HEMA: 2-hydroxyethyl methacrylate (Bimax) PVP K90: Poly(N-vinylpyrrolidone) (ISP Ashland) EGDMA: Ethylene glycol dimethacrylate (Esstech) TEGDMA: Tetraethylene glycol dimethacrylate (Esstech) Irgacure or Omnirad 1870: a blend of bis(2,6-dimethoxybenzoyl)-2,4,4-trimethyl-pentylphosphine oxide and 1-hydroxycyclohexyl-phenyl-ketone (IGM Resins or BASF or Ciba Specialty Chemicals) mPDMS: mono-n-butyl terminated, monomethacryloxypropyl terminated polydimethylsiloxane (M n =800-1500 Daltons) (Gelest) HO-mPDMS: mono-n-butyl terminated mono-(2-hydroxy-3-methacryloxypropyl)-propyl ether terminated polydimethylsiloxane (M n=400-1500g / mol) (Ortec or DSM-Polymer Technology Group) HO-mPDMS (n=4):

[0186] [ka] HO-mPDMS (n=15):

[0187] [ka] nBu: n-butyl XLMA: Bis-3-methacryloxy-2-hydroxypropyloxypropyl polydimethylsiloxane (Mn=2000 Daltons, average n=23 H 1 NMR(CDCl3, 500MHz)(Shin Etsu)

[0188] [ka] SiMAA: 2-propenoic acid, 2-methyl-2-hydroxy-3-[3-[1,3,3,3-tetramethyl-1-[(trimethylsilyl)oxy]disiloxanyl]propoxy]propyl ester (Toray), or 3-(3-(1,1,1,3,5,5,5-heptamethyltrisiloxan-3-yl)propoxy)-2-hydroxypropyl methacrylate Norbloc: 2-(2'-hydroxy-5-methacrylyloxyethylphenyl)-2H-benzotriazole (Janssen) RB247: 1,4-bis[2-methacryloxyethylamino]-9,10-anthraquinone TL03 Light: Phillips TLK 40W / 03 bulb LED: Light-emitting diode DO: 3,7-dimethyl-3-octanol (Vigon) 3M3P: 3-ethyl-3-pentanol DIW: Deionized water MeOH: Methanol IPA: Isopropyl alcohol DMF: N,N-dimethylformamide DMSO: dimethyl sulfoxide DCM or CH2Cl2: dichloromethane or methylene chloride DCE: 1,2-dichloroethane CDCl3: Deuterated chloroform PhOH: Phenol H2SO4: sulfuric acid HCl: Hydrochloric acid pTsOH: p-toluenesulfonic acid Ac2O: acetic anhydride Cs2CO3: Cesium carbonate SOCl2: Thionyl chloride NaH: sodium hydride CPTP: 2-(3-chloropropoxy)tetrahydro-2H-pyran NaI: sodium iodide Borate Buffer Packing Solution: 18.52 grams (300 mmol) of boric acid, 3.7 grams (9.7 mmol) of sodium borate decahydrate, and 28 grams (197 mmol) of sodium sulfate were dissolved in enough deionized water to fill a 2 liter volumetric flask.

[0189] Example 1 - Synthesis of 2-((9-(dicyanomethylene)-9H-thioxanthen-2-yl)oxy)ethyl methacrylate (Compound A) as shown in Scheme 1

[0190] [ka]

[0191] Thiosalicylic acid (6.3 g, ∼0.041 moles) was added to 60 mL of concentrated sulfuric acid over 5 minutes while constantly stirring the system. Phenol (18.8 grams, approximately 5 equivalents) was added to the reaction mixture in batches over 30 minutes, raising the temperature to 60°C. Once the exotherm subsided, the mixture was heated to 80°C and then held at that temperature for 2.5 hours with constant stirring. The reaction mixture was slowly added to 600 mL of boiling water while stirring the solution. A bright yellow precipitate formed upon dilution, and the suspension was heated for an additional 10 minutes before being cooled to room temperature. The solid was filtered through a fritted glass funnel. The yellow solid was washed three times with 300 mL of water, dried in a vacuum oven at 50°C, and used "as is" in the next step.

[0192] A suspension of 2-hydroxy-9H-thioxanthen-9-one (2.28 g, 0.01 mol), 2.0 grams of 2-chloroethyl methacrylate (0.0135 mol), and 5.0 grams of cesium carbonate (0.015 mol) in 25 mL of anhydrous DMSO was stirred overnight at 60°C under a nitrogen atmosphere. The mixture was cooled to room temperature and poured into 300 mL of ethyl acetate. The organics were extracted three times with 200 mL of 1% aqueous sodium chloride solution, and the volatiles were evaporated under reduced pressure. The remaining solid was washed with hexane on a fritted glass funnel, dried in a vacuum oven at 50°C, and used "as is" for the next step.

[0193] 2.4 grams of crude 2-(2-methacryloxyethoxy)-9H-thioxanthen-9-one (0.007 moles) was charged to a round-bottom flask equipped with a magnetic stir bar and a reflux condenser. The system was placed under a nitrogen atmosphere, and thionyl chloride (8 mL, 13.12 grams, 0.111 moles) was added to the flask. The mixture was heated at gentle reflux for 1 hour, after which the thionyl chloride was evaporated under reduced pressure. The flask was placed under a nitrogen atmosphere, and a solution of 1.39 grams of malononitrile (approximately 3 equivalents) and 5 grams of pyridine in 20 mL of dichloromethane was added, and the mixture was stirred at gentle reflux for an additional 2 hours.

[0194] Upon completion of the reaction, the mixture was diluted with 300 mL of ethyl acetate, and the organics were extracted with 0.2 N hydrochloric acid, followed by washing twice with 300 mL of water. The product was isolated as an orange solid after chromatography on silica gel using methylene chloride and acetone. Compound A: 1 H NMR (500 MHz, CDCl3) δ 1.92 (3H, bs, CH3), 4.31 (1H, t, J = 4.0 Hz), 4.51 (1H, t, 4.5 Hz), 5.56 (1H, bs, vinylic), 6.12 (1H, bs, vinylic), 7.13-8.11 (6H, ArH).

[0195] The UV-VIS transmittance spectrum of a 0.2 mM solution of Compound A in methanol is shown in Figure 1. The UV-VIS absorbance spectrum of a 0.2 mM solution of Compound A in methanol overlaid on a literature spectrum of macular pigment is shown in Figure 2.

[0196] Example 2 A reactive monomer mixture was prepared consisting of 77 weight percent of the formulation listed in Table 1 and 23 weight percent of diluent DO. The reactive monomer mixture was filtered under pressure through a 3 μm filter using a stainless steel syringe.

[0197] [Table 4]

[0198] The filtered reactive monomer mixture is degassed at ambient temperature by applying a vacuum (about 40 Torr) for at least about 20 minutes. Then, in a glove box containing a nitrogen gas atmosphere and less than about 0.1-0.2 percent oxygen gas, about 75 μL of the reactive mixture is dispensed at room temperature using an Eppendorf pipette onto a FC made from a 90:10 (w / w) Zeonor / TT blend. A BC made from a 90:10 (w / w) Z:TT blend is then placed onto the FC. The molds are equilibrated in the glove box for a minimum of 12 hours prior to dispensing. Pallets, each containing eight mold assemblies, are transferred into adjacent glove boxes maintained at 65°C and irradiated with about 1.5 mW / cm. 2 for 3 min using a 435 nm light-emitting diode light with a brightness of 2.5 mW / cm 2 Cure the lenses from top to bottom for 7 minutes using a 435 nm light-emitting diode light with an intensity of 1000 uV.

[0199] The lenses were manually removed from the molds and demolded by floating them in about 1 liter of 70 percent IPA for about 1 hour, followed by two 30-minute baths in fresh 70 percent IPA, then two 15-minute baths in fresh DIW, and then two 30-minute baths in packing solution. The lenses were equilibrated and stored in the borate-buffered packing solution. Those skilled in the art will appreciate that the exact lens demolding process, with respect to the concentration of the aqueous isopropanol, the number of washes with each solvent, and the duration of each step, can vary depending on the lens formulation and mold material. The goal of the lens demolding process is to demold all of the lenses without damage and to transition them from a diluent-swollen network to a packing-solution-swollen hydrogel.

[0200] Example 3 A reactive monomer mixture consisting of 77 weight percent of the formulation listed in Table 2 and 23 weight percent of diluent 3M3P was prepared. Compound A was first dissolved in DMA, and the resulting solution was then added to a separate solution containing all of the other components and diluents. The reactive monomer mixture was filtered under pressure through a 3 μm filter using a stainless steel syringe. The reactive monomer mixture was degassed at ambient temperature by applying a vacuum (approximately 40 Torr) for at least approximately 20 minutes. Next, in a glove box containing a nitrogen gas atmosphere and less than approximately 0.1-0.2 percent oxygen gas, approximately 75 μL of the reactive mixture was dispensed at room temperature using an Eppendorf pipette onto a FC made from a 90:10 (w / w) Zeonor / TT blend. A BC made from a 90:10 (w / w) Z:PP blend was then placed on the FC. The mold was allowed to equilibrate for a minimum of 12 hours in the glove box prior to dispensing. The pallets, each containing eight mold assemblies, were transferred into an adjacent glove box maintained at 65°C and exposed to approximately 1.5 mW / cm 2 for 3 min using a 420 nm light-emitting diode light with a brightness of 5 mW / cm 2 The lenses were cured from top to bottom for 5 minutes using a 420 nm light emitting diode light with an intensity of 10 ...

[0201] The lenses were manually removed from the molds and demolded by floating them in approximately 1 liter of 70% IPA for approximately 1 hour, followed by two 30-minute baths in fresh 70% IPA, two 15-minute baths in fresh DIW, and two 30-minute baths in packing solution. The lenses were equilibrated and stored in the borate-buffered packing solution. Those skilled in the art will appreciate that the exact lens demolding process, with respect to the concentration of the aqueous isopropanol, the number of washes with each solvent, and the duration of each step, can vary depending on the lens formulation and mold material. The goal of the lens demolding process is to demold all of the lenses without damage and to transition them from a diluent-swollen network to a packing solution-swollen hydrogel. The lenses were stored in vials. After equilibrating for one day, the lenses were inspected and sterilized by autoclaving at 122°C for 30 minutes.

[0202] [Table 5]

[0203] Example 4: Light irradiation Lenses prepared substantially as described in Example 3 were sealed in vials (containing packing solution) by known methods and exposed to light conditions in a glove box. The light conditions used are considered to be at least as severe as the ICH guideline Q1B mentioned above (thus, photodegradation equivalent to or less than that observed in this example can be expected under ICH guideline Q1B). The conditions were as follows: 10 vials, each containing one lens, were centered on a glass stage approximately 4 inches above an LED panel at approximately 435±5 nm and exposed to approximately 20 mW / cm for 40 hours at room temperature. 2 The animals were exposed to radiation.

[0204] UV / VIS absorbance spectra of the lenses collected at time zero (control) and 40 hours are shown in Figure 3. The absorbance values ​​in the range of 445 nm to 455 nm, as well as the percent change in absorbance after 40 hours of exposure relative to the control, are shown in Table 3. As is evident from Figure 3 and Table 3, test compounds that exhibit absorbance at 450 nm similar to that of natural macular pigment have the added advantage of exhibiting good photostability.

[0205] [Table 6]

[0206] [Embodiment] (1) A compound having a visible light absorption maximum of 430 nm to 480 nm and a full width at half maximum (FWHM) at said visible light absorption maximum of at least 35 nm and at most 100 nm, wherein said compound is photostable (e.g., as measured according to ICH guideline Q1B). (2) The compound according to embodiment 1, wherein the visible light absorption maximum is from 440 nm to 470 nm. (3) The compound according to any one of embodiments 1 to 2, wherein the FWHM at the visible light absorption maximum is at least 40 nm and at most 95 nm. (4) The compound of any one of embodiments 1-3, wherein the photostability comprises a loss of absorbance of no more than 20 percent at the visible light absorption maximum. (5) A compound having a visible light absorption maximum of 430 nm to 480 nm and a full width at half maximum (FWHM) at said visible light absorption maximum of at least 35 nm and at most 100 nm, said compound being more photostable than macular pigment (e.g., as measured according to ICH guideline Q1B).

[0207] (6) A compound comprising a chromophore, the chromophore having a substructure of formula I: [ka] wherein EWG at each occurrence is independently an electron-withdrawing group. (7) The compound of embodiment 6, wherein EWG at each occurrence is independently cyano, amide, ester, keto, or aldehyde. (8) The compound of any one of embodiments 6-7, wherein EWG at each occurrence is cyano. (9) having formula II, [ka] wherein EWG in each occurrence is independently an electron withdrawing group, n is 1, 2, or 3, and R 1 is independently in each occurrence H, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 thioalkyl, C3-C7 cycloalkyl, aryl, halo, hydroxy, amino, NR 3 R 4 , benzyl, SO3H, or SO3M (where M is a monovalent cation such as sodium or potassium), or -YP g and R 3 and R 4 are independently H or C1-C6 alkyl, Y is a linking group, and P g is a polymerizable group. (10) 2-(9H-thioxanthen-9-ylidene)malononitrile, or The compound according to embodiment 6, which is 2-((9-(dicyanomethylene)-9H-thioxanthen-2-yl)oxy)ethyl methacrylate.

[0208] (11) The compound of any one of embodiments 6 to 10, wherein the compound has a visible light absorption maximum of 430 nm to 480 nm and a full width at half maximum (FWHM) at the visible light absorption maximum of at least 35 nm and at most 100 nm, and the compound is photostable (e.g., as measured according to ICH guideline Q1B). (12) The compound of embodiment 11, wherein the visible light absorption maximum is from 440 nm to 470 nm. (13) The compound according to any one of embodiments 11-12, wherein the FWHM at the visible light absorption maximum is at least 40 nm and at most 95 nm. (14) The compound of any one of embodiments 11-13, wherein the photostability comprises a loss of absorbance of no more than 20 percent at the visible light absorption maximum. (15) The compound of any one of embodiments 6 to 14, wherein the compound has a visible light absorption maximum of 430 nm to 480 nm and a full width at half maximum (FWHM) at the visible light absorption maximum of at least 35 nm and at most 100 nm, and the compound is more photostable than macular pigment (e.g., as measured according to ICH guideline Q1B).

[0209] (16) An ophthalmic device comprising a compound according to any one of embodiments 1 to 15. (17) A contact lens or intraocular lens that is the polymerization reaction product of a reactive mixture comprising: a monomer suitable for making the ophthalmic device; and (b) a compound according to any one of embodiments 1 to 15. (18) An eyeglass or sunglass lens comprising: (a) a mineral material or an organic material, or a combination thereof; and (b) a compound according to any one of embodiments 1 to 15. (19) A compound, ophthalmic device, or spectacle lens according to any one of embodiments 1 to 18, which is imported into a country. (20) The compound, ophthalmic device, or spectacle lens of embodiment 19, wherein the country is the United States.

Claims

1. an ophthalmic device comprising the polymerization reaction product of a reactive mixture comprising a compound of Formula II, wherein the ophthalmic device is a contact lens, an intraocular lens, eyeglasses, or a sunglass lens; 【Chemical 1】 wherein EWG at each occurrence is independently cyano or aldehyde, n is 1, 2, or 3, and R １ is independently in each occurrence H, C １ ~C ６ Alkyl, C １ ~C ６ Alkoxy, C １ ~C ６ Thioalkyl, C ３ ~C ７ Cycloalkyl, aryl, halo, hydroxy, amino, NR ３ R ４ , benzyl, SO ３ H or SO ３ M (wherein M is a monovalent cation), or -Y-P ｇ and R ３ and R ４ are independently H or C １ ~C ６ alkyl, Y is a linking group, and P ｇ is a (meth)acryloyl group, and the compound of formula II has one or two -Y-P ｇ group, and the one or two -Y-P ｇ The groups may or may not be the same, ophthalmic device.

2. 10. The ophthalmic device of claim 1, which is a contact lens or an intraocular lens, wherein the reactive mixture comprises: (a) a monomer suitable for making the ophthalmic device; and (b) the compound of Formula II.

3. 10. The ophthalmic device of claim 1, wherein the ophthalmic device is a pair of eyeglasses or a pair of sunglass lenses, the ophthalmic device comprising: (a) a mineral material or an organic material, or a combination thereof; and (b) the polymerization reaction product.

4. The ophthalmic device of any one of claims 1 to 3, wherein both EWGs are cyano.

5. where n is 1 and R １ Is -Y-P ｇ 5. The ophthalmic device of claim 4, wherein:

6. 4. The ophthalmic device of any one of claims 1 to 3, wherein the compound of Formula II has a visible light absorption maximum between 430 nm and 480 nm and a full width at half maximum (FWHM) at the visible light absorption maximum of at least 35 nm and at most 100 nm, and wherein the compound of Formula II is photostable.

7. (i) the visible light absorption maximum is between 440 nm and 470 nm; and / or 7. The ophthalmic device of claim 6, wherein (ii) the FWHM at the visible light absorption maximum is at least 40 nm and at most 95 nm.

8. A compound of formula II, 【Chemistry 2】 where EWG is cyano, n is 1, and R １ Ha-Y-P ｇ Y is a linking group, and P ｇ is a (meth)acryloyl group.

9. 9. The compound of claim 8, wherein the compound has a visible light absorption maximum between 430 nm and 480 nm and a full width at half maximum (FWHM) at the visible light absorption maximum of at least 35 nm and at most 100 nm, and the compound is photostable.

10. 10. The compound of claim 9, wherein the photostability comprises a loss of absorbance at the visible light absorption maximum of 20 percent or less.

11. 9. The compound of claim 8, wherein the compound has a visible light absorption maximum between 430 nm and 480 nm and a full width at half maximum (FWHM) at the visible light absorption maximum of at least 35 nm and at most 100 nm, and wherein the compound is more photostable than macular pigment.

12. (i) the visible light absorption maximum is between 440 nm and 470 nm; and / or (ii) The compound according to any one of claims 9 to 11, wherein the FWHM at the visible light absorption maximum is at least 40 nm and at most 95 nm.

13. The compound of claim 8 which is 2-((9-(dicyanomethylene)-9H-thioxanthen-2-yl)oxy)ethyl methacrylate.

Images